The complement system in human pregnancy and preeclampsia

Abstract

Human pregnancy is a complex condition that poses significant challenges for women due to the necessity of a uterus for key processes such as fertilization, embryo implantation, fetal development, and childbirth. These processes are governed by immunological factors and accompanied by various physiological changes. For a successful pregnancy, maternal immune reprogramming is crucial because the developing embryo is considered a semi-allograft. Any immunological alteration during pregnancy induces recurrent pregnancy loss and other fetal–maternal health issues, including preeclampsia. However, despite advances in reproductive immunology, the exact immunopathogenesis of preeclampsia remains unclear. The complement system (CS) is an evolutionarily ancient and critical innate immune component that plays a significant role in maintaining immune homeostasis. The current article discusses the critical role of the CS in human pregnancy and how its dysregulation predisposes pregnant women to preeclampsia. The article introduces the concept of the Th1 to Th2 immunological shift as a prerequisite for a successful pregnancy and the evolution of decidualization via transposable elements, which recruit genes responsible for the process in the endometrium. The immune system plays a critical role in decidualization. The second section discusses the CS signaling pathway, its negative regulators, and the roles of the C3a/C3aR and C5a/C5aR1/C5aR2 or C5L2 axis in immune homeostasis. The third section elaborates on the role of the CS in the establishment of human pregnancy, such as fertilization, implantation, and fetal development. The fourth section describes maternal CS signaling alteration during successful human pregnancy. The fifth section describes the role of CS signaling in preeclampsia, including its systemic and local (placental) alterations and the responsible mechanisms. The article closes with future perspectives and a summary that describes important complement-based approaches for diagnosing and treating preeclampsia.

1 Introduction

Human pregnancy occurs in the very specialized organ, the uterus, which protects the developing embryo and fetus through its mucosal lining or decidua, making human pregnancy a unique immune challenge that further develops trained immunity with subsequent pregnancies (1–4). The maternal–fetal interaction during human pregnancy is an example of fetal allograft acceptance by the pregnant female as indicated by the shift from a pro-inflammatory Th1 immune response to an anti-inflammatory Th2 immune response (Figure 1) (5, 6). Furthermore, the maternal innate immune system plays a critical role in the successful outcome of human pregnancy. For example, uterine natural killer (uNK) cells are critical for the early embryonic establishment and spiral artery formation (1, 7). Along with the local uterine immune microenvironment, systemic factors, such as hormonal status and cytokine (pro- and anti-inflammatory) levels governing the systemic and local immunological status, determine pregnancy success (1). The details of fetal–maternal immune interactions during human pregnancy have been discussed elsewhere (4, 8–10).

Figure 1

The complement system (CS) is a component of the innate immune system. It is composed of more than 50 humoral components (fluid-phase proteins present in the blood, saliva, lymph, and interstitial fluids), which recognize pathogens and interact with antibodies (Abs)/immunoglobulins (IgG and IgM) and their cognate receptors expressed on different immune cells to maintain immune homeostasis (11, 12). Evolutionarily, the CS is one of the most ancient and primitive components of innate immunity (12, 13). For example, the complement component C3 and factor B genes comprising the central components of the CS originated at least 1,000 million (one billion) years ago (MYA) (13). Furthermore, developmental evolution studies focusing on the origin of pregnancy indicate that the recruitment of genes ancestrally expressed in other organ and tissue systems into endometrial expression transmitted new functions to the uterine endometrium, such as immune regulation and fetal–maternal signaling for a healthy pregnancy (14). The transposable elements (TEs) evolved/amplified prior to the divergence of eutherian mammals were critical for recruiting these genes to the endometrium to induce the development of decidualization, as indicated by the deposition of binding sites for master transcriptional regulators of endometrial stromal cell type identity and progesterone responsiveness to numerous genes across the genome (14). For example, the progesterone receptor (PGR) is the principal transcriptional effector of progesterone signaling and decidualization (14). Thus, decidualization in mammalian pregnancy has also evolved from acquiring genes from other organs required to maintain immune balance for normal functioning. The CS is one of the most ancient components of the innate immune system; therefore, it is critical to understand its role in human pregnancy and preeclampsia.

2 CS as a critical component of the immune system

The CS is composed of circulating or humoral components and its receptors called complement receptors (CRs), such as C1q, which is a pattern recognition receptor (PRR) of the complement component C1 (C1 is composed of C1r, C1q, and C1s) and mediates the complement recognition of surface-bound immunoglobulin (Ig) G and IgM, CR1 (CD35), CR2 (CD21), CR3 (CD11b/CD18 or Mac1), CR4 (CD11c/CD18), CRIg (VSIG4, expressed on Kupffer cells and several other tissue-resident macrophages), C3aR, C5aR1 (CD88), and C5aR2 or C5L2 (12, 15, 16). The liver is a major producer of circulating CS components (17, 18). However, epithelial, endothelial, and immune cells, such as neutrophils, monocytes and macrophages, dendritic cells (DCs), mast cells, B cells, and T cells, also produce different CS components or proteins (19). CS activation is a rapid innate immune response against invading pathogens, including microbe/pathogen-associated molecular patterns (MAMPs/PAMPs) and death/damage-associated molecular patterns (DAMPs), aimed at containing the infection and inflammation.

The CS activation further activates innate immune cells by promoting phagocytosis by producing opsonins, which induce opsonization, and the stimulation of different CRs (C3aR, C5aR1, and C5aR2) expressed on innate and adaptive immune cells, further activating both (innate and adaptive) arms of the immune system to maintain immune homeostasis. The CS activation pathway diverges mainly into three pathways: 1) classical CS activation, 2) lectin or mannan-binding lectin (MBL) pathway, and 3) alternative CS activation (Figure 2). It is critical to note that the alternative CS signaling pathway is evolutionarily older and that the classical CS signaling pathway evolved from it (20, 21). Complement component C3 activation is common to all three CS pathways, or all these pathways converge at C3 to form the end product, called the membrane attack complex (MAC), which is composed of C5bC6-9 (Figure 2). A brief description of all three CS signaling pathways forming the MAC has been discussed below and is shown in Figure 2.

Figure 2

Classical CS activation starts from the C1 component, which is composed of three components: C1q, C1r, and C1s (Figure 2A). C1q serves as a pattern recognition molecule (PRM) or PRR. It recognizes structural changes induced by IgM and/or IgG1, IgG2, and IgG3 Abs binding to pathogens, cell surfaces, or immune complexes (ICs) (Figure 2A). This recognition, or the C1q–pathogen/antigen/IC-IgM/IgG complex, activates two serine proteases (C1r and C1s) of C1. The enzymatically activated C1s recognizes complement component C4 and cleaves it into C4a (smaller fraction) and C4b (larger fraction) (Figure 2A). The biological role of C4a is not yet clear, whereas C4b within or near the Ig–C1 complex recruits fluid phase C2 and C1s, which process C2 to C2a (biological function unknown) and C2b (which is an active serine protease) (Figure 2A). The C4bC2b complex serves as a classical CS pathway C3 convertase, a central player for all three CS pathways (Figure 2A). C3 convertase promotes C3 activation, a central component of CS signaling pathways. C3 cleavage produces C3a (serves as an anaphylatoxin and induces C3a–C3aR interaction-mediated immune response) (Figure 2A), and C3b serves as an opsonin to aid in phagocytosis through its exposed thioester group that recognizes amino or hydroxyl groups on the target (15, 22, 23). The remaining C3b within C4bC2b forms a complex called C4bC2bC3b or C5 convertase (Figure 2A). The C2b component of C5 convertase cleaves C5 into C5a (serves as anaphylatoxin and inflammogen and induces C5aR1- and C5aR2-mediated immune functions) and C5b (mediates the activation of terminal pathway or MAC formation) (Figure 2A).

The lectin or MBL pathway is independent of Abs and shares many characteristics of classical and alternative CS signaling pathways (Figure 2B). The MBL or lectin pathway does not require C1 for its activation; instead, it depends on the recognition of PAMPs by MBL, three ficolins (Ficolins 1–3), and two collectins (Collectin-10 and Collectin-11), which have serine protease activity (Figure 2B). MBL and collectins (Collectin-10 and Collectin-11), due to their carbohydrate recognition domain, are part of the superfamily of fibrinogen-like proteins, whereas ficolins have a fibrinogen-like recognition domain and belong to the superfamily of fibrinogen-like proteins. Thus, MBL, ficolins, and collectins can recognize different carbohydrate entities, such as mannose of bacterial pathogens by MBL, N-acetylglucosamine (GlcNAc) of injured and dying cells by MBL and ficolins, and altered l-fucose and D-galactose patterns of cells under severe stress by ficolins and Collectin-10 and Collectin-11. Furthermore, the lectin pathway can also recognize the host DNA exposed on apoptotic cells, and Collectin-12 may activate the alternative CS signaling pathway in its soluble form in conjunction with properdin. MBL-associated serine protease-1 (MASP-1), MASP-2, and MASP-3 are MBL or lectin pathway serine proteases. MASP-1 and MASP-2 are associated with common collagen regions within MBL, ficolins, and collectins (Figure 2B), whereas MASP-3 activity is connected to the alternative CS pathway activation via the proteolytic cleavage of pro-Factor D (FD) to enzymatically active mature FD (Figure 2C). FD is a serine protease that is critical for activating the alternative CS signaling pathway by cleaving factor B (FB) and generating the C3 convertases C3(H₂O)Bb and C3bBb (discussed later in the alternative CS signaling pathway section) (24, 25). Adipocytes are the main producers of circulating FD (24, 25). The MASP-3-mediated cleavage of FD to its mature form prepares it for its initiation and amplification function of the alternative CS signaling pathway (25). The details of FD in the CS signaling pathway and complement-mediated inflammatory diseases have been discussed elsewhere (24, 25).

The MBL or lectin pathway recognizes the target molecule and autoactivates MASP-1, cleaving MASP-2 for its enzymatic activity toward C4 and C2 bound to initiating MBL, ficolins, and collectin–MASP-1/2 complexes. This is followed by classical CS signaling, such as forming a C4bC2b complex and a C3 convertase, activating C3 and C5 (Figure 2B). The C3 and C5 convertases of the lectin pathway are also known as lectin pathway convertases.

The alternative CS signaling pathway has been considered a separate CS activation pathway (Figure 2C). However, it can activate the CS itself and may account for approximately 80%–90% of the total complement activation, even in conditions triggered by classical or lectin/MBL pathways (26). For example, it idles in the serum constantly at low levels of activation, as 3%–5% of circulating C3 constantly exists in a hydrolyzed [C3(H₂O)] form, and its exposed thioester can spontaneously interact with complement targets, such as microbes in the peripheral circulation (blood, lymph, and interstitial fluids). Thus, C3(H₂O) is bound to the circulating pathogen, and C3b is deposited on the target surface during the classical or lectin/MBL pathway, recognized by the inactive serine protease, FB (Figure 2C). The C3(H₂O)/C3bFB complex interacts with another serine protease, FC, that cleaves FB into Ba and Bb (enzymatically active) units (Figure 2C). The smaller Ba subunit detaches itself from the C3(H₂O)/C3bFB complex, generating C3(H₂O)/C3bBb, the C3 convertase of the alternative CS signaling pathway (Figure 2C). The Bb component of the alternative CS signaling pathway’s C3 convertase cleaves C3 into C3a and C3b, as occurs during classical or lectin/MBL pathways (Figure 2C). The rapid production of C3bBbC3b (C4b2b3b) complexes during the alternative CS signaling pathway forms its C5 convertase, cleaving C5 into C5a and C5b (Figure 2C) (27). Properdin, a complement protein, along with stabilizing the C3 convertase complexes (C3bBbP) of the alternative CS signaling pathway, may also serve as an initiator or focus point for the subsequent C3b deposition during different conditions, such as apoptotic immune cell death as seen during acute infections, such as sepsis (27, 28). For example, properdin targets specific proteoglycans of apoptotic immune cells, serving as DAMPs and microbial PAMPs, and recruits C3b, which promotes phagocytic clearance of these pathogens and apoptotic cells (27).

The terminal pathway of CS signaling involves the convergence of all three CS signaling pathways that form the final and lytic component of the CS called the MAC, which forms pores in the targeted microbial surface (Figure 2D) (27). The MAC is composed C5b, C6, C7, C8, and C9 components of the CS (Figure 2D) (27, 29, 30). The complement components C6 to C9 are members of the MAC/perforin/cholesterol-dependent cytolysin (MACPF/CDC) protein superfamily. Thus, the MAC is the CS signaling end product that kills the target by forming pores. However, continuous CS activation is governed by several circulating or surface-bound regulators to prevent host damage, as described in Table 1.

2.1 CS in immunoregulation and immune homeostasis

The CS was first described as a critical antimicrobial defense component of innate immunity in circulation between 1888 and 1894 (165, 166). As discussed earlier, the activation of three components of the CS in response to different stimuli, such as Ag–Ab complexes, pathogens (PAMPs/MAMPs), and DAMPs, induces the release of different complement proteins, such as C3a, C3b, C5a, and C5b, and the formation of terminal MAC to clear the exo- or endogenous threat. C3a and C5a are critical immunomodulators that, in addition to serving as anaphylatoxins, also function as potent immunomodulatory agents through their cognate receptors (C3aR, C5aR1, and C5aR2 or C5L2), which are expressed on various innate and adaptive immune cells. Therefore, this section discusses the impact of C3a and C5a on immune cells expressing their cognate receptors.

2.1.1 Impact of C3a on various immune cells via direct interaction with C3aR

In addition to the CS signaling events, C3a can also be generated by different systemic proteases, such as thrombin and immune cell-derived cathepsin G and L (a lysosomal protease) (167–169). However, the cathepsin L (CTSL)-mediated cleavage of the C3 into C3a and C3b has been reported intracellularly in T cells, which maintains their survival through intracellular C3a–C3aR interaction-mediated downstream mammalian target of rapamycin complex 1 (mTORC1), Raptor, and p56 signaling, and extracellular C3a–C3aR promotes the generation of pro-inflammatory Th1 cells as indicated by the generation of pro-inflammatory cytokines, such as interferon-γ (IFN-γ) (170, 171). Resting T-cell lysosomes and endosomes contain C3, and its cleavage by the CTSL to generate “tonic” intracellular C3a is critical in maintaining homeostatic T-cell survival. The transfer of this intracellular C3a to the T-cell surface induces the autocrine pro-inflammatory cytokine production of the Th1 phenotype, which has been seen in T cells isolated from patients with autoimmune arthritis (170). The T cells of patients with autoimmune arthritis exhibit overactivated intracellular CS and IFN-γ production that can be blocked by targeting the intracellular CTSL. Furthermore, intracellular C3–C3aR signaling in intestinal Paneth cells [intestinal secretory epithelial cells with innate immune functions, such as the production and secretion of antimicrobial peptides (AMPs) and other immunomodulatory molecules] also regulates their mTORC1 signaling to enhance their intestinal protective function by supporting the expansion of intestinal stem cells (ISCs) in the intestinal crypts during acute inflammatory intestinal injury (172–174).

Interestingly, in contrast to the extracellular/secreted C3, the intracellular C3 generated via alternative translation in the cytosol is non-glycosylated and present in the reduced state. Intracellular non-glycosylated C3 is turned over by the ubiquitin–proteasome system (UPS) (175). Furthermore, C3 can also be retranslocated from the endoplasmic reticulum (ER) to the cytosol and structurally resembles extracellular/secreted C3. Notably, cytosolic C3 also exerts antimicrobial action in epithelial cells by opsonizing invasive pathogens, such as Staphylococcus aureus, decreasing the vacuolar escape, and impacting the bacterial survival by presenting the pathogen to phagocytes, such as macrophages (175). Furthermore, the cytosolic C3 in the β cells of the pancreas protects them from IL-1β-induced inflammatory cell death by interacting with and inhibiting the downstream Fyn-related kinase (FRK) (176, 177). Another study has indicated that the C3-mediated protective effect on pancreatic islet β cells involves AKT activation and c-Jun N-terminal kinase (JNK) inhibition upon treatment with pro-inflammatory cytokines, such as IL-1β and IFN-γ (178). Thus, in different cell types, such as T cells, Paneth cells, and pancreatic β cells, the cytosolic C3 supports their survival and division. Additionally, C3 present in the breast milk protects suckling mouse pups from Citrobacter rodentium-mediated enteric infection by shaping the evolving pup gut microbiota (killing of commensal Gram-positive Staphylococcus lentus B3) but without affecting the production of secretory antibodies in the breast milk (179, 180). A more detailed review of C3a–C3aR interactions on different immune cells would be too cumbersome for the main text and is summarized in Table 2.

2.1.2 Impact of C5a on various immune cells via direct interaction with C5aRs (C5aR1 and C5aR2 or C5L2)

The C5a generated during CS pathways due to the breakdown of C5 into C5a and C5b exerts immunomodulatory actions by interacting with C5aR1 (CD88) and C5aR2/C5L2. For example, C5a–C5aR1 interaction mediates potent leukocyte chemoattraction at the site of inflammation. It induces pro-inflammatory phenotype and functions on different immune cells during sterile and infectious inflammatory conditions, such as autoimmune diseases [rheumatoid arthritis (RA) and Crohn’s disease (CD)], allergies (asthma), ischemia–reperfusion injuries, and sepsis (235–239). However, the discovery of the second C5a receptor called C5L2 [a seven-transmembrane domain G protein-coupled receptor (GPCR)] or C5aR2 in 2000 has generated controversies in the previously established pro-inflammatory functions of C5a, as C5L2 has now been considered an anti-inflammatory C5aR (240, 241). C5L2 is also considered an active metabolic receptor, and its ligand C5a and C5a_desArg or acylation-stimulating protein (ASP) [the degraded/desarginated C5a fragment generated via enzymatic (carboxypeptidase) degradation-dependent endocytosis], is time-, clathrin-, and cholesterol-dependent (241, 242).

Circulating ASP levels increase in people with obesity, insulin resistance or Type 2 Diabetes Mellitus (T2DM), and metabolic syndrome, which increases monocyte chemoattractant protein-1 (MCP-1) and keratinocyte-derived chemokine (KC or IL-8) from their adipocytes through C5L2 or C5aR2 interaction without impacting IL-6 and adiponectin production (243, 244). The MCP-1 and KC production from adipocytes in response to ASP/C5L2 interaction involves phosphatidylinositol-3 kinase (PI3K) and nuclear factor-kappa B (NF-κB) activation (244). However, ASP via C5L2 interaction in macrophages does not induce MCP-1 and KC production. In contrast, the adipocyte-mediated production of these cytokines in the adipose tissue (AT) increases monocyte/macrophage chemotaxis and their inflammatory function (243). For example, C5a_desArg-induced C5L2 activation in adipocytes induces triglyceride synthesis and glucose and fatty acid (FA) uptake, which is absent in the adipocytes of C5L2 knockout mice (243–245).

C5L2 ligand binding induces their internalization and degradation, which decreases their extracellular expression level, which is a step to decrease the generation of profound or tissue-damaging complement-mediated inflammatory immune response (241). In contrast, C5aR1 internalizes ligands at a slow rate, which are further expelled back into the extracellular environment without undergoing degradation, which further aggravates the inflammatory cascade (241). Furthermore, Thr196Asn mutations in the C5L2 gene were associated with hyperlipidemia and retinitis pigmentosa (RP) in a Chinese family (246).

In humans, the GPR77 gene on chromosome 19, q13.33-13.34, is located downstream of the C5aR1 gene encoding C5aR2 or C5L2 (247). Interestingly, C5L2, belonging to C3a, C5a, and formyl Met-Leu-Ph (fMLP) receptors related to the chemokine receptor family, also binds to C3a with a moderate affinity (247, 248). However, the C3a binding to C5L2 can be easily displaced by C4a, indicating that C3a has a lower affinity to C5L2 than C5a. Moreover, the binding of anaphylatoxins (C3a and C5a) to C5L2 only increases the immune cell degranulation potential upon cross-linking high-affinity immunoglobulin E (IgE) receptor by a pertussis toxin-sensitive mechanism. C5L2 binding affinity to C5a is similar to that of C5aR1. C5L2 binds to C5a_desArg with a higher affinity than C5aR1 (242, 247). The C5L2 transcripts have been widely expressed in different organs, such as the spleen, testis, brain (frontal cortex, hippocampus, and hypothalamus), heart, lung, liver, kidney, adrenal gland, thyroid gland, spinal cord, ovary, and colon, and in immune and non-immune cells, like granulocytes, immature DCs, adipocytes, and skin fibroblasts, but not in monocyte-derived macrophages (MDMs) (248–253). Table 3 shows the impact of C5a and C5aR1/C5L2 or C5aR2 interaction on different immune cells.

3 CS in human pregnancy

3.1 CS in human fertilization

The CS is critical for women’s reproductive health and successful pregnancy (fertilization to childbirth). For example, the human female reproductive tract (FRT), comprising the ovaries, fallopian tubes, uterine endometrium, myometrium, and cervix, expresses complement regulatory proteins (CRPs), such as CD55 and CD59 (protectin), and CD46 [membrane cofactor protein (MCP)] (Figure 3) (301). The CRPs (CD55, CD59, and CD46) are overexpressed in stressed endometrial cells, indicating that their endometrial cells develop a complement-mediated lysis process, modifying their inflammatory outcome in different immune-mediated inflammatory diseases (IMIDs) (302). However, all CS components/proteins of classical and alternative pathways are present in the uterine, tubal, and follicular fluids (303).

Figure 3

Moreover, human unfertilized eggs (plasma membrane and zona pellucida) and pre-implantation embryos express CD55/DAF and CD59, preventing them from complement attack (Figure 3) (304–306). Unfertilized oocytes do not express CD46, but it appears at the six-to-eight cell embryonic stage on their cell membrane as the first embryonic human gene expression begins (Figure 3) (304, 305). Interestingly, oocytes and pre-implantation embryos do not express complement receptor 1 (CR1 or CD35)/C3b/C4b receptor and major histocompatibility complex 1 (MHC-1) proteins (303, 304). Of note, mRNA transcripts of soluble complement inhibitors, including C4b-binding protein (C4BP beta chain), factor I, and clusterin, are present in oocytes through their eight-cell stage embryo blastomeres (306).

The mRNA transcripts of central complement activating components, such as C3 and C5, along with their activators (factor B and D, C3 activators in the alternative pathway) and other complement cascade proteins (C1s and C2) of the classical and MBL CS pathways are also present in oocytes and embryos, indicating that their transcripts remain after fertilization (306). Human embryos also express C5aR1, CR2, and CD18 (Figure 3). CD18/CD11b serves as CR3, and CD18/CD11c comprises CR4. C1q is present at all embryonic developmental stages (Figure 3) (306). The C3b/iC3b complex on the cell surface of different early embryonic developmental stages indicates targeting of the embryo by the activated complement. The inactivated C3, known as C3d, is present on the cell surface of the developing embryo, indicating that a complement activation check is crucial for embryo development (Figure 3) (306). However, C5 is expressed on the zona pellucida surface of the oocyte but not on the surface of blastomeres (Figure 3). Interestingly, oocytes and blastomeres do not have intracellular C3 and C5 but express C4bp and factor H on their cell surface (306). Factor H is also present in the zona pellucida of oocytes (Figure 3).

In addition to the expression of complement proteins in the human female ovum, the sperm also expresses different complement components. For example, human sperms express C1 inhibitor (C1-INH), C1qR (cC1qR and gC1qR/p33), CD46, CD55, and CD59, which may be critical for their survival and motility (Figure 3) (307–309). CD46, CD55, and CD59 are expressed on the inner acrosomal membrane of a human sperm, which are critical for the fertilization process but do not protect sperm from anti-sperm antibodies and complement-mediated immune attack (310). Furthermore, C1q promotes the agglutination of capacitated sperms, and C1qR (cC1qR and gC1qR) expression increases in this process (311, 312). The cleaved complement component C3b on sperm acrosome (formed during acrosome reaction) binds with CR1 and CR3 of the oocyte to facilitate the fertilization process (Figure 3) (313). Factor H, but not CD46, serves as a cofactor in C3b cleavage, which contributes to the fertilization process (314). Human sperm CD46 also contributes to the survival of acrosome-reacted spermatozoa in the FRT by modulating CS activation (308). The complement activation critical for the fertilization process is initiated by the C-reactive protein (CRP) and is dependent on other complement components, such as C1q, C2, and factor B (314). Hence, complement components (expressed in ovum and sperm) are critical for mammalian/human fertilization to create a new life.

3.2 CS in embryo implantation and spiral artery formation

The trophoblast is a local producer of complement components in the maternal decidua, serving as a primary source of complement components C3 and C4 at the maternal–fetal interface (315). Local IFN-γ at the maternal–fetal interface positively impacts trophoblast C3 and C4 production. Uterine or decidual NK (dNK) cells comprise the majority of immune cells at the time of blastocyst implantation, are the primary source of local IFN-γ during the early stages of human pregnancy, and are critical mediators of spiral artery formation (1, 316–319). Human circulating NK cells express C3aR, which migrate to the uterine microenvironment during pregnancy to serve as dNK or uNK cells, comprising 70% of the decidual lymphocyte population. The C3a–C3aR interaction on NK cells inhibits their cytotoxic action (320, 321). Additionally, C3b deposition on target cells also inhibits NK cell cytotoxicity (322). It is well known that human dNK cells exhibit lower cytotoxic activity and secrete high levels of immunoregulatory cytokines and molecules to support a healthy pregnancy (323–325). Therefore, it would be interesting to explore how homeostatic complement activation during embryo implantation influences dNK cell functions (decreasing cytotoxic function but increasing their secretory function to release immunoregulatory cytokines) to support their pregnancy functions.

Human decidual stroma widely expresses and secretes complement component C1q, which interacts with proteins expressed on decidual extracellular matrix (DEM) and promotes trophoblast adhesion and migration by activating ERK1/2 mitogen-activated protein kinases (MAPKs) to promote trophoblast invasion of decidua and placental development (326, 327). Furthermore, epithelial–mesenchymal transition (EMT) is critical for trophoblast differentiation and maternal–fetal interface establishment, as indicated by the differentiation of trophoblast [extravillous trophoblast (EVT)] cells from proximal epithelial phenotype to a distal invasive mesenchymal phenotype called interstitial trophoblast penetrating the maternal decidua basalis and into the maternal myometrium (328). Complement components, such as the C3a–C3aR axis, promote EMT during fibrosis and cancer metastasis (230, 329–331). Trophoblast cells also exhibit characteristics of cancer cells and pseudotumorigenesis to nourish the developing embryo (332–334). Thus, CS components are critical for embryo implantation and placental development to maintain a healthy human pregnancy.

4 Impact of pregnancy on maternal circulating CS components

The circulating levels of C3a, C4a, and C5a increase in normal pregnant women and remain elevated throughout pregnancy, from 20 weeks post-gestation to the newborn’s delivery (335–337). However, some studies have indicated a decrease in circulating C5a with no alteration in C3a and C4a levels in women with healthy pregnancies than non-pregnant women (338). Moreover, an early (first trimester of pregnancy) increase in circulating C3a levels is associated with adverse pregnancy outcomes (336, 339). Nevertheless, a study from China has indicated that the circulating C1q, C5a, and C5b-9 (MAC) levels in the first and second trimesters are similar to those of non-pregnant healthy women (340). In contrast, increased levels of C3, properdin, C1q, factors H and B, C4, and adipsin and decreased levels of circulating C2 and C5a have been associated with successful implantation as indicated by a study comprising Middle Eastern (Qatar) women with obesity undergoing in vitro fertilization (IVF)-assisted conception (341). The maternal circulating C1-INH level decreases during this period (336). Thus, in a healthy pregnancy, maternal circulating complement components, such as C3a, adipsin (FD), and C5a, increase above baseline during the second and third trimesters and remain stable afterward (340, 342). However, women with preeclampsia develop higher circulating adipsin levels later in their pregnancy (343). In addition, catalyzing the rate-limiting step of alternative CS signaling pathway activation, adipsin (FD) is also involved in MAC formation and C3a and C5a anaphylatoxin generation (27, 344, 345). Thus, increased circulating adipsin levels during pregnancy and preeclampsia indicate associated metabolic and cardiovascular changes, as circulating adipsin levels are directly associated with the metabolic and cardiovascular health of an individual (346–348).

The MBL–MASP2 activity also increases during normal pregnancy (349). Any alteration in circulating complement components beyond their regulatory/protective function at the early stages of pregnancy (first trimester) causes an abnormal pregnancy outcome (337, 350–352). Preeclampsia is one of the conditions that affect the fetus and mother, which is discussed in the following section, specifically in the context of the complement system to maintain the article’s specificity. Moreover, preeclampsia predisposes surviving women to develop hypertension, cardiovascular diseases (CVDs), and metabolic syndrome later in life (353, 354).

5 CS in preeclampsia

Clinically, preeclampsia is characterized by the new onset of hypertension and proteinuria in pregnant women or any other maternal signs of maternal vascular dysfunction, such as edema or dysfunction of any other organ (liver, kidney, pulmonary, cerebral, or visual) or restricted fetal growth after 20 weeks of gestation (355, 356). A comparative preeclampsia study based on American College of Obstetricians and Gynecologists (ACOG) and International Society for the Study of Hypertension in Pregnancy (ISSHP) definitions of preeclampsia at term gestational age (≥37 0/7 weeks) to identify adverse maternal and perinatal outcomes has indicated the inclusion of broad definition for preeclampsia, as it can better identify women and babies at risk of adverse outcomes (357). For example, the more inclusive ISSHP definition of maternal end-organ dysfunction seemed to be more sensitive in identifying adverse maternal and perinatal outcomes associated with preeclampsia than following the less inclusive ACOG definition (357). Moreover, the inclusion of uteroplacental dysfunction (particularly when angiogenic factors are included) to diagnose preeclampsia on its broad definition optimizes preeclampsia identification in pregnant women and babies at risk (357). In contrast, eclampsia represents severe convulsions/seizures in women with gestational hypertension or preeclampsia (355, 358). The etiology of preeclampsia, including placentation’s impact, has been described elsewhere and will not be discussed in the current article (359, 360).

It is interesting to note that preeclampsia was described in the early 20th century, while eclampsia was recognized much earlier, with descriptions dating back thousands of years (355, 361). Immunology, including the study of the innate immune system, is also a new branch of modern medicine. For example, the field of the innate immune system was revolutionized after the discovery of macrophages/phagocytosis by Elia Metchnikoff in 1882 (362). Furthermore, the functional studies associated with the CS were first described between 1888 and 1894, although evolutionarily, the CS is the most ancient component of the innate immune system, as a complement component called C3-like protein has existed a billion years ago (BYA) (12, 13, 166). Although immunological advances in preeclampsia immunopathogenesis have been made, information about the CS in preeclampsia is scarce (363–369). Furthermore, inflammation (local and systemic) also plays a critical role in preeclampsia immunopathogenesis, and the CS is a key mediator of the inflammatory process (370–373). Therefore, understanding the role of this (CS) evolutionarily ancient innate immune component in preeclampsia pathogenesis is critical to understanding its immunology.

5.1 Maternal circulating CS components during preeclampsia

Recent studies have indicated the alteration of CS (classical, lectin, and alternative complement activation pathways) proteins in maternal and fetal circulation and placental tissues (342, 374–376). Nevertheless, data are not equivocal for some maternal circulating complement proteins, which may be due to race, ethnicity, comorbidity, and geographical locations, as race and ethnicity also play a crucial role in the origin, pathophysiology, and outcomes of preeclampsia (377). For example, women with preeclampsia have significantly lower circulating properdin and C4 levels but higher factor B (Ba and Bb) than women with normal pregnancy, which starts to increase during early pregnancy (first trimester) (350, 374, 375, 378, 379). The decreased circulating C1q and factor H levels in patients with early- and late-onset severe preeclampsia have also been observed (379). However, another study has indicated a significant increase in circulating C1q and C4d levels in late-onset severe preeclampsia (LOSPE). C3a, C5a, and MAC levels also increase in maternal circulation with early-onset severe preeclampsia (EOSPE) and LOSPE (380–382). The placentae of pregnant women with preeclampsia express lower C3aR and C5aR levels than those of women with normal pregnancy (381, 383). Nevertheless, a positive correlation between higher serum C3a and C5a levels in women with preeclampsia with circulating angiotensin II type 1 (AT1) receptor agonistic autoantibody (AT1-AA) has been observed (381). AT1-AA is one of several mediators of hypertension during pregnancy, along with increasing soluble fms-like tyrosine kinase-1 (sFlt1) and soluble endoglin (CD105) (sEng), and endothelin-1, which are elevated in women with preeclampsia (384–386). Increased sEng and sFlt1 in EOSPE directly correlate with MAC levels and, inversely, with circulating C3a levels (382). Thus, increased AT1-AA in circulation during pregnancy may activate the CS signaling pathway to generate potent anaphylatoxins, such as C3a and C5a, to induce EOSPE. Increased circulating sFlt1 during pregnancy induces hypertension, proteinuria, and glomerular endotheliosis, which are associated with preeclampsia (387). In addition to the circulating complement component alteration during preeclampsia, the cell surface component, such as CD93 (C1qRp or C1qR1 expressed on endothelial cells), level decreases in the circulation, whereas its level increases in the serum during the first trimester of normal pregnancy (388). Therefore, further studies are needed in this direction.

A study of women with singleton pregnancies in Colombia has indicated the association between decreased maternal circulating factor H in the first trimester and spontaneous preterm birth (389). Recently, a genome-wide association study (GWAS) in Finland has identified five rare heterozygous factor H variants (L3V, R127H, R166Q, C1077S, and N1176K) only in women with severe preeclampsia (390, 391). Of these five factor H variants in women with severe preeclampsia, variants R127H and C1077S are associated with normal factor H synthesis without its release in the circulation. In contrast, variants R166Q and N1176K are associated with normal factor H secretion with reduced binding to C3b, causing dysregulated CS activation associated with severe preeclampsia (390). However, the authors could not find any defect in patients with severe preeclampsia exhibiting the L3V factor H variant. Thus, CS-associated genetic mutations can also determine women’s susceptibility or resistance to developing preeclampsia during pregnancy. The decreased maternal circulating factor H levels have also been associated with preeclampsia in women from European countries, such as the Netherlands, Finland, Norway, Italy, and the United Kingdom, without any increase in circulating anti-factor H autoantibodies (392, 393). Furthermore, the placentae [decidual stromal cells (DSCs), decidual endothelial cells (DECs), and EVTs] of women with preeclampsia express lower factor H levels (mRNA and protein) than those of women with normal pregnancy (393). In addition to factor H, other C3b regulators, such as MCP and Complement Factor I (CFI) genetic mutants [typically associated with atypical hemolytic uremic syndrome (aHUS)], in pregnant women with systemic lupus erythematosus (SLE) or antiphospholipid antibodies (APL Ab) have been identified, indicating their higher susceptibility to develop preeclampsia than normal women (394). Moreover, normal pregnant women (without SLE and APL Ab) with hypomorphic MCP and CFI genetic variants are more susceptible to developing preeclampsia than those without these variants.

Nevertheless, despite inconsistencies in different circulating CS components, a systematic meta-analysis of selected 41 studies out of a total of 456 studies has retrieved results consistently reporting reduction of C4, C3, and factor H and increase of C4d, Bb, factor D, C3a, C5a, and MAC or C5b-9 in maternal circulation during preeclampsia than in women with normal pregnancies (395). In addition to altered circulating CS components/proteins, the CR variants, such as CR3 (CD11b/18, Mac-1, or integrin αMβ2) variant M441K, display a trend toward an increased adhesion to iC3b, which is most significantly associated with preeclampsia in the Finnish Genetics of Pre-eclampsia Consortium (FINNPEC) cohort (396). The CR4 variant A251T increases C4 adhesion to iC3b, and the W48R CR4 variant decreases CR4 binding to iC3b, which may have functional consequences on the CS signaling pathway to impact preeclampsia susceptibility/resistance and severity in the population (396, 397). Even 14 variants within nine genes coding for components of the MAC or C5b-9 have a strong association with preeclampsia (398). For example, two missense variants (rs200674959 and rs147430470) of C5 are strongly associated with preeclampsia predisposition among pregnant women. Moreover, the C6 variant rs41271067 predisposes women to preeclampsia, whereas its rs114609505 variant protects against preeclampsia (398).

In addition to the classical and alternative CS components, the circulating MBL pathway components are critical for pregnancy and preeclampsia (399); for example, H-ficolin and MASP-3 of the MBL pathway of the CS decrease in women with preeclampsia (399). Ficolin-2 and ficolin-3 are also lower in pregnant women with preeclampsia than in those with normal pregnancy (400). The decreased plasma ficolin-2 level of women with preeclampsia positively correlates with circulating placental growth factor (PIGF) and inversely correlates with circulating sFlt1. However, pregnant women with preeclampsia have higher plasma MBL concentration than women with normal pregnancy (376). Women with MBL codon 54 gene polymorphism are protected from preeclampsia development (401). The protective effect of the MBL codon 54 gene against preeclampsia may be due to low MBL production, as low-MBL production genotypes are considered disease (preeclampsia) modifiers (402). Therefore, further studies are needed to establish preeclampsia’s genetic and immunological mechanisms with MBL pathway dysregulation.

Additionally, second-trimester amniotic fluids of pregnant (singleton) women have shown upregulated C3a and factor Bb before the onset of preeclampsia, indicating that CS activation during early pregnancy is associated with early-onset preeclampsia (403). Elevated C5a levels in the amniotic fluid of pregnant women developing preeclampsia have also been observed (404). Women with preeclampsia exhibit urinary excretion of the MAC because of an antiangiogenic state (high circulating sFlt1 and low PIGF and VEGF levels) associated with severe preeclampsia (405–407). Hence, altered maternal complement components during pregnancy are critical for the onset and severity of preeclampsia.

5.2 Placental CS components and preeclampsia

The complement proteins expressed on placental tissues are also critical for a healthy pregnancy, and their alteration plays a critical role in inducing preeclampsia (408). For example, a term placenta obtained after a healthy delivery expresses complement inhibitor C4b-binding protein (C4bBP) on its outer layer (syncytial knots of syncytiotrophoblast) that facilitates material exchange between the mother and the developing fetus (409). C4d is rarely present in the placentae of normal pregnant women, but its expression increases in syncytiotrophoblasts of women with preeclampsia (408, 410). In contrast, factor H is abundant in the placental tissue stroma of normal pregnancy, which is decreased in the placentae obtained from women with preeclampsia (409). EVTs express CD46, CD55, and CD59 in all three trimesters of normal pregnancy (411, 412). The placentae obtained from women with preeclampsia overexpress CD55 and CD59 (408). The C1q, MBL, and properdin expression in the placenta do not change between a healthy pregnancy and preeclampsia (408). However, despite no difference between control and preeclampsia in control and EOSPE patients, C1q expression decreases in LOSPE patients, which needs further investigation (408, 409). Moreover, the placental macrophages of women with preeclampsia overexpress C5a, and their trophoblasts overexpress C5aR (413). The C5a–C5aR interaction on trophoblast cells polarizes them toward an anti-angiogenic phenotype by balancing their angiogenic factors, such as sFlt1 or soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and PIGF (410, 413). Another study has indicated an increase in placental sFlt1 and PIGF in women with preeclampsia, which increases maternal circulating sFlt1 and falls post-delivery (387). The upregulated C4d, sFlt1, and MAC in the placentae of women with preeclampsia correlate well, indicating the aberrant CS activation. C5a–C5aR axis inhibition has prevented aberrant placental development by decreasing sFlt1 levels and rescued pregnancies (413, 414). Furthermore, C3a also induces the upregulation of cellular sFlt1 in human syncytiotrophoblast cells, and upregulated MAC induces its release (415). Increased sFlt1 and decreased PIGF-mediated angiogenic imbalance suppress the expression and secretion of factor H from placental endothelial cells, further activating the CS to cause endothelial cell damage and systemic vascular dysfunction, hypertension, and proteinuria during preeclampsia (416). Fetal cord blood factor B levels do not vary during healthy pregnancy and preeclampsia, and other complement components (C1q, C3, C4, and C3d) are much lower than those in healthy maternal circulation (375, 417). Nevertheless, C3d levels increase in fetal cord blood with the degree of placental inflammation, indicating their increase during preeclampsia (418).

It is interesting to mention that the placentae of women with SLE and APL syndrome show higher classical CS pathway activation, including higher C4d (a most important classical CS pathway activation marker) expression at the feto-maternal interface, leading to fetal loss and preeclampsia development, than normal healthy pregnant women (408, 419, 420). However, a very recent case–control study from Finland comprising pregnancies from 2000 to 2018 has indicated no statistical difference between pregnant women with SLE and normal pregnant women in the occurrence of preeclampsia or any other congenital malformation despite a significantly shorter duration of pregnancies and a more urgent need for cesarean section among pregnant women with SLE (421). A retrospective study comprising all SLE pregnancies during a period of 10 years (2006–2015) from a single center in Malaysia has indicated the development of complicated pregnancies, including preeclampsia, fetal losses, and the need for cesarean deliveries (422). Another retrospective study by a different group in Malaysia comprising pregnant SLE women for the period January 2008 to 2020 indicated the development of complicated pregnancies, such as SLE flares, preeclampsia, and eclampsia (423). Another retrospective study from Beijing, China, comprising 105 SLE-associated pregnancies for the period from January 1990 to December 2008, has also indicated complicated pregnancies, fetal loss, and preeclampsia development in active SLE pregnant women (424). A retrospective cohort study of 149 pregnancies in 98 women with SLE conducted over 10 years in Oman has also indicated the development of preeclampsia and eclampsia in these women along with an increase in SLE-associated pathologies, such as lupus nephritis and flares (425). The data from four retrospective studies performed in Sub-Saharan African pregnant women with SLE (137 pregnancies in 102 women) over a 26-year period have indicated a higher incidence of preeclampsia and aggravation of SLE symptoms, such as lupus nephritis and SLE flares, which further increased adverse pregnancy outcomes, including preeclampsia (426). This difference [geographical and ethnic origin (Europe, Asia, and Africa)] indicates the genetic and environmental impact on SLE and other autoimmune conditions affecting pregnancy outcomes, including preeclampsia, which must be explored. SLE and APL syndrome-mediated immune alteration, including CS pathway association with pregnancy loss and preeclampsia discussion, is beyond the scope of the current article and has been discussed elsewhere (427–429).

5.3 Mechanisms of CS pathway activation during preeclampsia

We have discussed earlier that altered CS signaling pathways are critical players in the onset and severity of preeclampsia. However, we do not know the triggers activating the CS pathway to induce inflammatory consequences that support and aggravate preeclampsia pathogenesis and outcome. For example, maternal hypertension and proteinuria (endothelial dysfunction) after 20 weeks of gestation are significant characteristics of preeclampsia, along with increased platelet aggregation and the hyperactivation of the coagulation system (430, 431). The pathogenesis of preeclampsia varies in nulliparous women compared with women with pre-existing vascular diseases, metabolic syndrome, multifetal gestation, and/or previous preeclampsia. However, some pregnant women with HELLP (hemolysis, elevated liver enzymes, or low platelet counts) syndrome (10%–15%) or eclampsia (38%) may not exhibit hypertension or proteinuria, which are associated with higher rates of maternal and fetal morbidities than in mild preeclampsia (432, 433). Interestingly, HELLP syndrome exhibits elevated maternal CS pathway activation as indicated by the increased systemic levels of different complement components, such as C5a, MAC, CFH, and CFH-related 1 and 3 (CFHR1 and 3), which are comparable to preeclampsia systemic values of complement components (434–437).

Furthermore, HELLP syndrome patients with complement gene variants exhibit poorer clinical outcomes than those with no complement gene variants. These patients have higher complement mutation frequency, including rare germline mutations in the alternative CS pathway (CFHR1, CFHR3, CFI, CFB, and CD46) than women with preeclampsia, having similar rates of variants as the control population (438, 439). Thus, pregnant women with complement gene variants are more likely to progress from preeclampsia to HELLP syndrome, where gene variants and pregnancy provide first and second hits, like other complement disorders, such as aHUS and paroxysmal nocturnal hemoglobinuria (PNH). Furthermore, a clinical trial with eculizumab, a long-acting human monoclonal antibody targeting C5 to block its cleavage to C5a and C5b, has shown positive results in phase 1 clinical trials of pregnant women with early-onset HELLP syndrome (440). Hence, CS activation is critical for the pathogenesis and severity of preeclampsia and HELLP syndrome. Therefore, it is critical to identify factors that dysregulate the CS activation during preeclampsia and its severe forms.

5.3.1 Maternal factors associated with increased risk of preeclampsia and their association with complement dysregulation

Women facing infertility associated with polycystic ovary syndrome (PCOS) and recurrent pregnancy loss (RPL; defined as ≥3 consecutive embryonic losses before 10 weeks’ gestation or ≥2 fetal losses after 10 weeks’ gestation) are more prone to develop preeclampsia (441). The immune system plays a critical role in the pathogenesis of PCOS and RPL, and the CS is a critical component of the immune system. Studies have shown that high maternal circulating C3 and C4 levels via CS signaling pathway activation before conception are associated with RPL independent of MBL CS pathways and other components of immunity, such as B cells and antibodies (442–445). Furthermore, women with specific mutations in C4BP carrying C4BP gene polymorphism R120H also suffer from RPL due to decreased C3b degradation that elevates their circulating C3b level (446). Another study has indicated several C3 gene variants associated with defective secretion/function of C3 in European women (n = 192) who suffered from RPL (447). Thus, dysregulated CS activation, such as the alternative CS signaling pathway in women who suffered RPL previously, predisposes them to develop preeclampsia during a successful pregnancy due to their altered CS signaling pathway, even in the presence of healthy placental development. Furthermore, fasting circulating complement components, such as C3 and C3a (desArg), are higher in PCOS women with insulin resistance, which increases to a similar extent in the control and PCOS groups (448). However, higher factor H levels are present in the circulation in PCOS women with obesity (448, 449).

Non-obese, non-insulin-resistant women with PCOS have higher systemic alternative and classical CS signaling pathway components, such as C3, iC3b, properdin, and C4 levels (450). Further study has indicated that upregulated alternative CS pathway components, such as C3, properdin, factor B, and factor I, are elevated in non-obese patients with PCOS, which further increases with obesity (449, 450). Systemic C5a levels are also increased in normal-weight women and women with obesity suffering from PCOS (449). Hence, activation and terminal CS pathway components are altered in PCOS women, which increases their propensity to develop RPL. Thus, we can speculate that infertile women (due to RPL and PCOS) with otherwise normal sexual function and immune components may have altered CS components, which increases their propensity to develop preeclampsia.

Elevated body mass index (BMI) and obesity are other definite preeclampsia risk factors (431, 451–454). AT comprises adipocytes and stromal vascular fraction (SVF), containing different cell types, such as preadipocytes, fibroblasts, and immune cells (macrophages and T cells). Adipocytes are the primary source of FD, a critical player in the alternative CS signaling pathway activation (455). Along with FD, other alternative CS components, such as C3, factor B, factor H, factor I, and properdin, are overexpressed in ATs, which increase with BMI and obesity status (455). Furthermore, adipocytes express C3aR and C5aRs (C5aR1 and C5aR2), which, via their corresponding ligands (C3a and C5a), increase the local and systemic inflammation along with increasing insulin resistance (244, 456, 457). Women with obesity with elevated circulating Bb (active protease, generated during the alternative CS signaling pathway) and C3a levels compared with the control group are more likely to develop preeclampsia (458, 459). Thus, women with obesity, high BMI, and insulin resistance or glucose tolerance have hyperactivated alternative CS signaling, which predisposes them to develop preeclampsia during their pregnancy. Hence, pre-pregnancy CS component dysregulation due to the above-mentioned factors in women increases their chances of facing preeclampsia during their pregnancy.

6 Future perspective and conclusion

Preeclampsia is a disease that specifically occurs during pregnancy; therefore, the placenta and dysregulated maternal immune response are key factors for its pathogenesis. However, immunological advances in pregnancy and preeclampsia have now clarified that poor placentation is not the only driving force behind preeclampsia pathogenesis but rather serves as a critical factor for preeclampsia predisposition (431). The degree of maternal physiological reaction, including the immune response severity, determines the predisposition to preeclampsia and its severity. For example, the immune system governs the effective allotransplantation of the fetus in the uterus of the pregnant woman by modifying the maternal local (uterine) and systemic immune response, vascular, and coagulatory functions, which are further governed by the hormonal and psychogenic changes taking place in a pregnant woman (460–465). Hence, any pre-pregnancy immune dysfunction can be lethal to the future mother and developing fetus, as the CS is the first and rapid immune component of innate immunity; therefore, its homeostatic levels during pregnancy are critical for a healthy outcome.

Hypertension development during pregnancy is a critical factor in the development of preeclampsia. A study has indicated systemic elevation of the clusterin (a complement regulatory protein) in pregnant women during pre-hypertension disorder of pregnancy (pre-HDP) development, which proved to be the critical factor for HDP development (466). Further studies have indicated increased clusterin systemic levels before the onset of preeclampsia clinical symptoms in pregnant women that increase with preeclampsia severity (467–469). Moreover, clusterin plays a critical role in the decidualization process by interacting with the triggering receptor expressed on myeloid cells 2 (TREM-2) receptor expressed on decidual cells, and its alteration may impact placental development, including trophoblast invasion (467, 470). The higher clusterin levels in the placenta inhibit MAC formation; therefore, it will be interesting to investigate the systemic clusterin and MAC levels during normal human pregnancy and preeclampsia.

Furthermore, aberrant and persistent CS activation (local and systemic) elevates systemic MAC or C5b-9 and C1q, causing systemic vasculitis or thromboinflammation that impairs endothelial function, which may cause hypertension (471–476). Thus, aberrant CS activation in pregnant women and their placentae may induce endothelial damage that may cause hypertension and elevate circulating endothelial cells, further aggravating the CS, predisposing them to preeclampsia, and increasing its severity (476, 477). For example, fetal endothelial cell damage and CS dysregulation (elevated MAC and C3a levels but decreased factor H and Bb) have been observed in pregnancies complicated by preeclampsia (478).

C3 is a critical component in hypertension pathogenesis due to its maintenance effect on undifferentiated mesenchymal stem cells (MSCs), and maternal and placental C3a levels are upregulated in women with preeclampsia, indicating aberrant CS activation (479). Furthermore, increased maternal circulating C5a in women with preeclampsia is positively correlated with maternal blood pressure and arterial stiffness (413). Targeting the CS during preeclampsia may prevent associated organ damage, such as renal manifestations, as the kidneys are among the most affected organs in preeclampsia (480). Hence, CS proteins must be checked for a healthy pregnancy.

Women with preeclampsia also exhibit a hypercoagulable state than women with normal pregnancy at an early stage of the disease (481). Women with preeclampsia have elevated circulating levels of factor VIII, von Willebrand factor (vWF; due to endothelial cell damage/inflammation), the thrombin–antithrombin complex (TAT), D dimers, soluble fibrin, and thrombomodulin levels than women with normal pregnancy (481–483). Increased fibrin deposition in women with preeclampsia occurs in the glomerulus sub-endothelium, spiral arteries, decidual components, and occlusive lesions of placental vasculature (484, 485). Fibrin deposition activates the classical CS signaling pathway by interacting with C1q by covalent interaction mediated by FXIIIa (53). However, this fibrin–C1q interaction is antagonized by factor H, which is downregulated in women with preeclampsia.

The activated CS signaling pathway in patients with preeclampsia can stimulate the extrinsic coagulation system pathway to form thrombin by increasing the tissue factor (TF) activity on different cells, such as endothelial cells, as evolutionarily the CS and coagulation system have a common origin and interact to maintain homeostasis and hemostasis (486–489). Moreover, overproduced plasmin, a protease generated in response to thrombin production and fibrin deposition, also serves as C5 convertase and cleaves C5 into C5a and C5b to induce the inflammatory cascade and the assembly of procoagulant C5b-9 or the MAC (490). In addition to C5 cleavage, plasmin also cleaves C3 into C3a, which is upregulated in women with preeclampsia (491). Furthermore, inflammatory events, including organ injuries, complement (increase in C5a levels), coagulation (thrombin–antithrombin complexes), activation, and cross-talk, are very early events, which have also been reported in patients with preeclampsia (491). Several other coagulation pathway components, such as Factor Xa, thrombin, FIXa, and FXIa, also cleave C3 and C5 into biologically active C3a and C5a capable of exerting their pro-inflammatory effects (491, 492). Further maternal proteomics-based study has indicated the increased deposition of C5b-9 or the MAC and vWF in the endothelial cells of women with early-onset severe preeclampsia, indicating that the complement and coagulation systems are the critical pathways for early-onset severe preeclampsia (493). Thus, aberrant complement activation not only dysregulates immune homeostasis but also affects the coagulation system, hypertension, and metabolism to initiate and increase the severity of preeclampsia.

Moreover, increased circulating C3a levels have been observed in women with depression; therefore, it may be interesting to investigate whether increased circulating C3a levels predispose women to develop preeclampsia upon getting pregnant (494). Increased circulating C3a levels during pregnancy are a critical biomarker not only for preeclampsia prediction but also for depression during pregnancy, as the Edinburgh postnatal depression scale (EPDS) alone is not perfectly sufficient to detect major depressive disorder during pregnancy (495). Interestingly, more than 10% of pregnant women in high-income countries, such as the United States, have depression during pregnancy (496).

6.1 Conclusion

Measuring different circulating complement proteins in pregnant women may serve as a biomarker for early preeclampsia detection. Targeting the CS in pregnant women with preeclampsia will complement normal pregnancy and associated organ damage. Understanding CS signaling during preeclampsia will further help to track future maternal health issues, such as metabolic, cardiovascular, and neurologic disorders in survivors. Complementing helps in a healthy pregnancy, but decomplementing will equip us to fight against preeclampsia and other future health issues in preeclampsia survivors. Therefore, future studies are warranted to understand the CS signaling pathways’ alteration and their mechanism of action in human pregnancy and preeclampsia.

References

• 1

  KumarVMedhiB. Emerging role of uterine natural killer cells in establishing pregnancy. Iranian J Immunol. (2008) 5:71–81. doi: 10.22034/iji.2008.48555

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  FeyaertsDJoostenIvan der MolenRG. A pregnancy to remember: trained immunity of the uterine mucosae. Mucosal Immunol. (2021) 14:539–41. doi: 10.1038/s41385-020-00362-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3

  ZhouJZWaySSChenK. Immunology of uterine and vaginal mucosae: (Trends in immunology 39, 302-314, 2018). Trends Immunol. (2018) 39:355. doi: 10.1016/j.it.2018.02.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  SolanoME. Decidual immune cells: Guardians of human pregnancies. Best Pract Res Clin Obstetrics Gynaecology. (2019) 60:3–16. doi: 10.1016/j.bpobgyn.2019.05.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  WegmannTGLinHGuilbertLMosmannTR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. (1993) 14:353–6. doi: 10.1016/0167-5699(93)90235-D

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  VinceGSJohnsonPM. Is there a Th2 bias in human pregnancy? J Reprod Immunol. (1996) 32:101–4. doi: 10.1016/S0165-0378(96)00995-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  MaleVMoffettA. Natural killer cells in the human uterine mucosa. Annu Rev Immunol. (2023) 41:127–51. doi: 10.1146/annurev-immunol-102119-075119

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  SacksGSargentIRedmanC. An innate view of human pregnancy. Immunol Today. (1999) 20:114–8. doi: 10.1016/S0167-5699(98)01393-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9

  ColamatteoAFuscoCMicilloTD’HoogheTde CandiaPAlviggiCet al. Immunobiology of pregnancy: from basic science to translational medicine. Trends Mol Med. (2023) 29:711–25. doi: 10.1016/j.molmed.2023.05.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  OreficeR. Immunology and the immunological response in pregnancy. Best Pract Res Clin Obstetrics Gynaecology. (2021) 76:3–12. doi: 10.1016/j.bpobgyn.2020.07.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  KolevMLe FriecGKemperC. Complement–tapping into new sites and effector systems. Nat Rev Immunol. (2014) 14:811–20. doi: 10.1038/nri3761

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  KumarV. The complement system, toll-like receptors and inflammasomes in host defense: three musketeers’ one target. Int Rev Immunol. (2019) 38:131–56. doi: 10.1080/08830185.2019.1609962

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  NonakaMKimuraA. Genomic view of the evolution of the complement system. Immunogenetics. (2006) 58:701–13. doi: 10.1007/s00251-006-0142-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  LynchVJNnamaniMCKapustaABrayerKPlazaSLMazurECet al. Ancient transposable elements transformed the uterine regulatory landscape and transcriptome during the evolution of mammalian pregnancy. Cell Rep. (2015) 10:551–61. doi: 10.1016/j.celrep.2014.12.052

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  MastellosDCHajishengallisGLambrisJD. A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol. (2024) 24:118–41. doi: 10.1038/s41577-023-00926-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  SonM. Understanding the contextual functions of C1q and LAIR-1 and their applications. Exp Mol Med. (2022) 54:567–72. doi: 10.1038/s12276-022-00774-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  QinXGaoB. The complement system in liver diseases. Cell Mol Immunol. (2006) 3:333–40.

  • Google Scholar

• 18

  ThorgersenEBBarratt-DueAHaugaaHHarboeMPischkeSENilssonPHet al. The role of complement in liver injury, regeneration, and transplantation. Hepatology. (2019) 70:725–36. doi: 10.1002/hep.30508

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  LubbersRvan EssenMFvan KootenCTrouwLA. Production of complement components by cells of the immune system. Clin Exp Immunol. (2017) 188:183–94. doi: 10.1111/cei.12952

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20

  FarriesTCSteuerKLAtkinsonJP. Evolutionary implications of a new bypass activation pathway of the complement system. Immunol Today. (1990) 11:78–80. doi: 10.1016/0167-5699(90)90031-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  FarriesTCAtkinsonJP. Evolution of the complement system. Immunol Today. (1991) 12:295–300. doi: 10.1016/0167-5699(91)90002-B

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  RicklinDReisESMastellosDCGrosPLambrisJD. Complement component C3 - The “Swiss Army Knife” of innate immunity and host defense. Immunol Rev. (2016) 274:33–58. doi: 10.1111/imr.12500

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  CoulthardLGWoodruffTM. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol. (2015) 194:3542–8. doi: 10.4049/jimmunol.1403068

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  SekineHMachidaTFujitaT. Factor D. Immunol Rev. (2023) 313:15–24. doi: 10.1111/imr.13155

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25

  BarrattJWeitzI. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.712572

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26

  HarboeMMollnesTE. The alternative complement pathway revisited. J Cell Mol Med. (2008) 12:1074–84. doi: 10.1111/j.1582-4934.2008.00350.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  RicklinDHajishengallisGYangKLambrisJD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. (2010) 11:785–97. doi: 10.1038/ni.1923

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  FearonDTAustenKF. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. (1975) 142:856–63. doi: 10.1084/jem.142.4.856

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  Müller-EberhardHJ. The killer molecule of complement. J Invest Dermatol. (1985) 85:47s–52s. doi: 10.1111/1523-1747.ep12275445

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  PodackERTschoppJ. Membrane attack by complement. Mol Immunol. (1984) 21:589–603. doi: 10.1016/0161-5890(84)90044-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  PradaAEZahediKDavisAE. 3rd, Regulation of C1 inhibitor synthesis. Immunobiology. (1998) 199:377–88. doi: 10.1016/S0171-2985(98)80042-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  GitlinDBiasucciA. Development of γG, γA, γM, β 1C/β 1A, C′ 1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, α 1-antitrypsin, orosomucoid, β-lipoprotein, α 2-macroglobulin, and prealbumin in the human conceptus. J Clin Invest. (1969) 48:1433–46. doi: 10.1172/JCI106109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  SchmaierAHSmithPMColmanRW. Platelet C1- inhibitor. A secreted alpha-granule protein. J Clin Invest. (1985) 75:242–50. doi: 10.1172/JCI111680

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  SchmaierAHAmentaSXiongTHedaGDGewirtzAM. Expression of platelet C1 inhibitor. Blood. (1993) 82:465–74. doi: 10.1182/blood.V82.2.465.465

  • CrossRef
  • Google Scholar

• 35

  ArmbrustTSchwöglerSZöhrensGRamadoriG. C1 esterase inhibitor gene expression in rat Kupffer cells, peritoneal macrophages and blood monocytes: modulation by interferon gamma. J Exp Med. (1993) 178:373–80. doi: 10.1084/jem.178.2.373

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36

  KatzYStrunkRC. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J Immunol. (1989) 142:2041–5. doi: 10.4049/jimmunol.142.6.2041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37

  HarpelPCCooperNR. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest. (1975) 55:593–604. doi: 10.1172/JCI107967

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38

  ChenCHBoackleRJ. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses. Clin Immunol Immunopathol. (1998) 87:68–74. doi: 10.1006/clin.1997.4515

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  ChenCHLamCFBoackleRJ. C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities. Immunology. (1998) 95:648–54. doi: 10.1046/j.1365-2567.1998.00635.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40

  SchreiberADKaplanAPAustenKF. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest. (1973) 52:1402–9. doi: 10.1172/JCI107313

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  RatnoffODPenskyJOgstonDNaffGB. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C’1r subcomponent of the first component of complement by serum C’1 esterase inhibitor. J Exp Med. (1969) 129:315–31. doi: 10.1084/jem.129.2.315

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  JiangHWagnerEZhangHFrankMM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med. (2001) 194:1609–16. doi: 10.1084/jem.194.11.1609

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43

  CaiSDavisAE. III, complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion 1. J Immunol. (2003) 171:4786–91. doi: 10.4049/jimmunol.171.9.4786

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  GompelsMMLockRJAbinunMBethuneCADaviesGGrattanCet al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. (2005) 139:379–94. doi: 10.1111/j.1365-2249.2005.02726.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45

  HallamTMSharpSJAndreadiAKavanaghD. Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic. Immunobiology. (2023) 228:152410. doi: 10.1016/j.imbio.2023.152410

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46

  NilssonSCSimRBLeaSMFremeaux-BacchiVBlomAM. Complement factor I in health and disease. Mol Immunol. (2011) 48:1611–20. doi: 10.1016/j.molimm.2011.04.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  ColeJLHousleyGAJr.DykmanTRMacDermottRPAtkinsonJP. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci U.S.A. (1985) 82:859–63.

  • Google Scholar

• 48

  CserhalmiMPappABrandusBUzonyiBJózsiM. Regulation of regulators: Role of the complement factor H-related proteins. Semin Immunol. (2019) 45:101341. doi: 10.1016/j.smim.2019.101341

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  KissMGPapac-MiličevićNPorschFTsiantoulasDHendrikxTTakaokaMet al. Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. Immunity. (2023) 56:1809–1824.e1810. doi: 10.1016/j.immuni.2023.06.026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50

  PouwRBBrouwerMCde GastMvan BeekAEvan den HeuvelLPSchmidtCQet al. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera. Blood Adv. (2019) 3:621–32. doi: 10.1182/bloodadvances.2018025692

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51

  MahajanSJacobAKelkarAChangAMcSkimmingDNeelameghamSet al. Local complement factor H protects kidney endothelial cell structure and function. Kidney Int. (2021) 100:824–36. doi: 10.1016/j.kint.2021.05.033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52

  WuJWuY-QRicklinDJanssenBJCLambrisJDGrosP. Structure of complement fragment C3b–factor H and implications for host protection by complement regulators. Nat Immunol. (2009) 10:728–33. doi: 10.1038/ni.1755

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  KangYHVarghesePMAiyanAAPondmanKKishoreUSimRB. Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots. Front Immunol. (2024) 15:1368852. doi: 10.3389/fimmu.2024.1368852

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  CiprianiVTierneyAGriffithsJRZuberVSergouniotisPIYatesJRWet al. Beyond factor H: The impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations. Am J Hum Genet. (2021) 108:1385–400. doi: 10.1016/j.ajhg.2021.05.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  Lorés-MottaLvan BeekAEWillemsEZandstraJvan MierloGEinhausAet al. Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. Am J Hum Genet. (2021) 108:1367–84. doi: 10.1016/j.ajhg.2021.06.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  SándorNSchneiderAEMatolaATBarbaiVHBenczeDHammadHHet al. The human factor H protein family – an update. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1135490

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  JózsiMTortajadaAUzonyiBGoicoechea de JorgeERodríguez de CórdobaS. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. (2015) 36:374–84. doi: 10.1016/j.it.2015.04.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  HebeckerMJózsiM. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J Biol Chem. (2012) 287:19528–36. doi: 10.1074/jbc.M112.364471

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  Bernabéu-HerreroMEJiménez-AlcázarMAnterJPintoSSánchez ChinchillaDGarridoSet al. FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol. (2015) 67:276–86. doi: 10.1016/j.molimm.2015.06.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  LiXZongJSiS. Complement Factor H related protein 1 and immune inflammatory disorders. Mol Immunol. (2022) 145:43–9. doi: 10.1016/j.molimm.2022.03.117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  BlomAMVilloutreixBODahlbäckB. Complement inhibitor C4b-binding protein—friend or foe in the innate immune system? Mol Immunol. (2004) 40:1333–46. doi: 10.1016/j.molimm.2003.12.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62

  WernerLMCrissAK. Diverse functions of C4b-binding protein in health and disease. J Immunol. (2023) 211:1443–9. doi: 10.4049/jimmunol.2300333

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  SeyaTHolersVMAtkinsonJP. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J Immunol (Baltimore Md.: 1950). (1985) 135:2661–7. doi: 10.4049/jimmunol.135.4.2661

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  SeyaTNakamuraKMasakiTIchihara-ItohCMatsumotoMNagasawaSet al. and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b. Mol Immunol. (1995) 32:355–60. doi: 10.1016/0161-5890(94)00157-V

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  BlomAMKaskLDahlbäckB. Structural requirements for the complement regulatory activities of C4BP*. J Biol Chem. (2001) 276:27136–44. doi: 10.1074/jbc.M102445200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66

  SjöbergAPTrouwLAMcGrathFDGHackCEBlomAM. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein1. J Immunol. (2006) 176:7612–20. doi: 10.4049/jimmunol.176.12.7612

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  VarghesePMMurugaiahVBeiragNTempertonNKhanHAAlrokayanSHet al. C4b binding protein acts as an innate immune effector against influenza A virus. Front Immunol. (2021) 11. doi: 10.3389/fimmu.2020.585361

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68

  BierschenkDPapac-MilicevicNBreschIPKovacicVBettoniSDziedzicMet al. C4b-binding protein inhibits particulate- and crystalline-induced NLRP3 inflammasome activation. Front Immunol. (2023) 14:1149822. doi: 10.3389/fimmu.2023.1149822

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  TrappRGFletcherMForristalJWestCD. C4 binding protein deficiency in a patient with atypical Behçet’s disease. J Rheumatol. (1987) 14:135–8.

  • Pubmed Abstract
  • Google Scholar

• 70

  SchwaebleWJReidKBM. Does properdin crosslink the cellular and the humoral immune response? Immunol Today. (1999) 20:17–21. doi: 10.1016/s0167-5699(98)01376-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  PillemerLBlumLLepowIHRossOAToddEWWardlawAC. The properdin system and immunity: I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. (1954) 120:279–85. doi: 10.1126/science.120.3112.279

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  FerreiraVP. Chapter 27 - properdin. In: BarnumSScheinT, editors. The Complement FactsBook, 2nd ed. USA: Academic Press (2018). p. pp 283–293.

  • Google Scholar

• 73

  HourcadeDE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement*. J Biol Chem. (2006) 281:2128–32. doi: 10.1074/jbc.M508928200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74

  MedicusRGGötzeOMüller-EberhardHJ. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med. (1976) 144:1076–93. doi: 10.1084/jem.144.4.1076

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  DensenPWeilerJMGriffissJMHoffmannLG. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med. (1987) 316:922–6. doi: 10.1056/NEJM198704093161506

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  SchlesingerMNaveZLevyYSlaterPEFishelsonZ. Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections. Clin Exp Immunol. (1990) 81:423–7. doi: 10.1111/j.1365-2249.1990.tb05350.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  LintonSMMorganBP. Properdin deficiency and meningococcal disease–identifying those most at risk. Clin Exp Immunol. (1999) 118:189–91. doi: 10.1046/j.1365-2249.1999.01057.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  FijenCAvan den BogaardRSchipperMMannensMSchlesingerMNordinFGet al. Properdin deficiency: molecular basis and disease association. Mol Immunol. (1999) 36:863–7. doi: 10.1016/S0161-5890(99)00107-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  SullivanKE. Chapter 81 - inherited complement deficiencies. In: RimoinDPyeritzRKorfB, editors. Emery and Rimoin’s Principles and Practice of Medical Genetics, Sixth Edition. Academic Press, Oxford (2013). p. pp 1–13. doi: 10.1016/B978-0-12-383834-6.00085-9

  • CrossRef
  • Google Scholar

• 80

  TschoppJChonnAHertigSFrenchLE. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. J Immunol. (1993) 151:2159–65. doi: 10.4049/jimmunol.151.4.2159

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  MassriMToonenEJMSargBKremserLGrasseMFleischerVet al. Complement C7 and clusterin form a complex in circulation. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1330095

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  ChauhanAKMooreTL. Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Clin Exp Immunol. (2006) 145:398–406. doi: 10.1111/j.1365-2249.2006.03135.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  DoudevskiIRostagnoACowmanMLiebmannJRitchRGhisoJ. Clusterin and complement activation in exfoliation glaucoma. Invest Ophthalmol Visual Sci. (2014) 55:2491–9. doi: 10.1167/iovs.13-12941

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  HochgrebeTTHumphreysDWilsonMREasterbrook-SmithSB. A reexamination of the role of clusterin as a complement regulator. Exp Cell Res. (1999) 249:13–21. doi: 10.1006/excr.1999.4459

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  SchvartzISegerDShaltielS. Vitronectin. Int J Biochem Cell Biol. (1999) 31:539–44. doi: 10.1016/S1357-2725(99)00005-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  MilisLMorrisCASheehanMCCharlesworthJAPussellBA. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol. (1993) 92:114–9. doi: 10.1111/j.1365-2249.1993.tb05956.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  ZhengXSaundersTLCamperSASamuelsonLCGinsburgD. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U.S.A. (1995) 92:12426–30. doi: 10.1073/pnas.92.26.12426

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  SinghBSuY-CRiesbeckK. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol. (2010) 78:545–60. doi: 10.1111/j.1365-2958.2010.07373.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  JangY-CTsouRGibranNSIsikFF. Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. Surgery. (2000) 127:696–704. doi: 10.1067/msy.2000.105858

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  HayashidaMHashimotoKIshikawaTMiyamotoY. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model. Int J Exp Pathol. (2019) 100:72–82. doi: 10.1111/iep.12306

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  FearonDT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med. (1980) 152:20–30. doi: 10.1084/jem.152.1.20

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  DustinML. Complement receptors in myeloid cell adhesion and phagocytosis. Microbiol Spectr. (2016) 4. doi: 10.1128/microbiolspec.mchd-0034-2016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  KazatchkineMDFearonDT. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). Immunodefic Rev. (1990) 2:17–41.

  • Pubmed Abstract
  • Google Scholar

• 94

  SteinigerBTrabandtMBarthPJ. The follicular dendritic cell network in secondary follicles of human palatine tonsils and spleens. Histochem Cell Biol. (2011) 135:327–36. doi: 10.1007/s00418-011-0799-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  AsokanRBandaNKSzakonyiGChenXSHolersVM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol. (2013) 53:99–110. doi: 10.1016/j.molimm.2012.07.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  IidaKNadlerLNussenzweigV. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med. (1983) 158:1021–33. doi: 10.1084/jem.158.4.1021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  WagnerCOchmannCSchoelsMGieseTStegmaierSRichterRet al. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol Immunol. (2006) 43:643–51. doi: 10.1016/j.molimm.2005.04.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  KovácsKGMácsik-ValentBMatkóJBajtayZErdeiA. Revisiting the coreceptor function of complement receptor type 2 (CR2, CD21); coengagement with the B-cell receptor inhibits the activation, proliferation, and antibody production of human B cells. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.620427

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  Vorup-JensenTJensenRK. Structural immunology of complement receptors 3 and 4. Front Immunol. (2018) 9:2716. doi: 10.3389/fimmu.2018.02716

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  SándorNKristófKParéjKPapDErdeiABajtayZ. CR3 is the dominant phagocytotic complement receptor on human dendritic cells. Immunobiology. (2013) 218:652–63. doi: 10.1016/j.imbio.2012.07.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  WagnerCHänschGMStegmaierSDeneflehBHugFSchoelsM. The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol. (2001) 31:1173–80. doi: 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  KleinEDi RenzoLYefenofE. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol Immunol. (1990) 27:1343–7. doi: 10.1016/0161-5890(90)90041-W

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  VikDPFearonDT. Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. J Immunol. (1987) 138:254–8. doi: 10.4049/jimmunol.138.1.254

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  WalbaumSAmbrosyBSchützPBachgACHorsthemkeMLeusenJHWet al. Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. J Biol Chem. (2021) 296. doi: 10.1016/j.jbc.2021.100256

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  LukácsiSNagy-BalóZErdeiASándorNBajtayZ. The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes. Immunol Lett. (2017) 189:64–72. doi: 10.1016/j.imlet.2017.05.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  TabordaCPCasadevallA. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity. (2002) 16:791–802. doi: 10.1016/S1074-7613(02)00328-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  LimJWiedemannATzircotisGMonkleySJCritchleyDRCaronE. An essential role for talin during αMβ2-mediated phagocytosis. Mol Biol Cell. (2007) 18:976–85. doi: 10.1091/mbc.e06-09-0813

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  KazatchkineMDJouvinMHWilsonJGFischerEFischerA. Human diseases associated with C3 receptor deficiencies. Immunol Lett. (1987) 14:191–5. doi: 10.1016/0165-2478(87)90100-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  Bermejo-JambrinaMBlatzerMJauregui-OnievaPYordanovTEHörtnaglPValovkaTet al. CR4 signaling contributes to a DC-driven enhanced immune response against complement-opsonized HIV-1. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.02010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  WiesmannCKatschkeKJYinJHelmyKYSteffekMFairbrotherWJet al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature. (2006) 444:217–20. doi: 10.1038/nature05263

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  GorganiNNHeJQKatschkeKJHelmyKYXiHSteffekMet al. Complement receptor of the Ig superfamily enhances complement-mediated phagocytosis in a subpopulation of tissue resident macrophages. J Immunol. (2008) 181:7902–8. doi: 10.4049/jimmunol.181.11.7902

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  ZengZSurewaardBGJWongCHYGeogheganJAJenneCNKubesP. CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne gram-positive bacteria. Cell Host Microbe. (2016) 20:99–106. doi: 10.1016/j.chom.2016.06.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  VogtLSchmitzNKurrerMOBauerMHintonHIBehnkeSet al. VSIG4, a B7 family–related protein, is a negative regulator of T cell activation. J Clin Invest. (2006) 116:2817–26. doi: 10.1172/JCI25673

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  AndersonDCSpringerTA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p 150, 95 glycoproteins. Annu Rev Med. (1987) 38:175–94. doi: 10.1146/annurev.me.38.020187.001135

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  LiszewskiMKAtkinsonJP. Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections. Curr Opin Immunol. (2021) 72:126–34. doi: 10.1016/j.coi.2021.04.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  LiszewskiMKKemperC. Complement in motion: the evolution of CD46 from a complement regulator to an orchestrator of normal cell physiology. J Immunol. (2019) 203:3–5. doi: 10.4049/jimmunol.1900527

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  LiszewskiMKAtkinsonJP. Complement regulator CD46: genetic variants and disease associations. Hum Genomics. (2015) 9:7. doi: 10.1186/s40246-015-0029-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  RichardsAKempEJLiszewskiMKGoodshipJALampeAKDecorteRet al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci. (2003) 100:12966–71. doi: 10.1073/pnas.2135497100

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  CocuzziESzczotkaLBBrodbeckWGBardensteinDSWeiTMedofME. Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF). Clin Exp Immunol. (2001) 123:188–95. doi: 10.1046/j.1365-2249.2001.01408.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  DhoSHLimJCKimLK. Beyond the role of CD55 as a complement component. Immune Netw. (2018) 18:e11. doi: 10.4110/in.2018.18.e11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  MarschangPSodroskiJWürznerRDierichMP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol. (1995) 25:285–90. doi: 10.1002/eji.1830250147

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  KwonY-CKimHMeyerKDi BisceglieAMRayR. Distinct CD55 isoform synthesis and inhibition of complement-dependent cytolysis by hepatitis C virus. J Immunol. (2016) 197:1127–36. doi: 10.4049/jimmunol.1600631

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  CapassoMDurrantLGStaceyMGordonSRamageJSpendloveI. Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol. (2006) 177:1070–7. doi: 10.4049/jimmunol.177.2.1070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124

  FinbergRWWhiteWNicholson-WellerA. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol (Baltimore Md.: 1950). (1992) 149:2055–60. doi: 10.4049/jimmunol.149.6.2055

  • CrossRef
  • Google Scholar

• 125

  ParkerCOmineMRichardsSNishimuraJ-IBesslerMWareRet al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. (2005) 106:3699–709. doi: 10.1182/blood-2005-04-1717

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  OzenA. CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann’s disease. Immunol Rev. (2019) 287:20–32. doi: 10.1111/imr.12715

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  Ruiz-ArgüellesALlorenteL. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev. (2007) 6:155–61. doi: 10.1016/j.autrev.2006.09.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  MeriSWaldmannHLachmannPJ. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest. (1991) 65:532–7.

  • Pubmed Abstract
  • Google Scholar

• 129

  CouvesECGardnerSVoisinTBBickelJKStansfeldPJTateEWet al. Structural basis for membrane attack complex inhibition by CD59. Nat Commun. (2023) 14:890. doi: 10.1038/s41467-023-36441-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  SpearGTLurainNSParkerCJGhassemiMPayneGHSaifuddinM. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol (Baltimore Md.: 1950). (1995) 155:4376–81. doi: 10.4049/jimmunol.155.9.4376

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131

  McGrealEPIkewakiNAkatsuHMorganBPGasqueP. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol. (2002) 168:5222–32. doi: 10.4049/jimmunol.168.10.5222

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  TennerAJ. C1q receptors: regulating specific functions of phagocytic cells. Immunobiology. (1998) 199:250–64. doi: 10.1016/S0171-2985(98)80031-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  ChevrierSGentonCKalliesAKarnowskiAOttenLAMalissenBet al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci U.S.A. (2009) 106:3895–900. doi: 10.1073/pnas.0809736106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134

  IkewakiNYamaoHKulskiJKInokoH. Flow cytometric identification of CD93 expression on naive T lymphocytes (CD4(+)CD45RA (+) cells) in human neonatal umbilical cord blood. J Clin Immunol. (2010) 30:723–33. doi: 10.1007/s10875-010-9426-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  VemuriKde Alves PereiraBFuenzalidaPSubashiYBarberaSvan HoorenLet al. CD93 maintains endothelial barrier function and limits metastatic dissemination. JCI Insight. (2024) 9. doi: 10.1172/jci.insight.169830

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  NorsworthyPJFossati-JimackLCortes-HernandezJTaylorPRBygraveAEThompsonRDet al. Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol. (2004) 172:3406–14. doi: 10.4049/jimmunol.172.6.3406

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  NepomucenoRRRuizSParkMTennerAJ. C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity. J Immunol. (1999) 162:3583–9. doi: 10.4049/jimmunol.162.6.3583

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138

  TossettaGPianiFBorghiCMarzioniD. Role of CD93 in health and disease. Cells. (2023) 12. doi: 10.3390/cells12131778

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139

  KishoreUReidKB. C1q: structure, function, and receptors. Immunopharmacology. (2000) 49:159–70. doi: 10.1016/S0162-3109(00)80301-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140

  EggletonPTennerAJReidKB. C1q receptors. Clin Exp Immunol. (2000) 120:406–12. doi: 10.1046/j.1365-2249.2000.01218.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  SimRBMoestrupSKStuartGRLynchNJLuJSchwaebleWJet al. Interaction of C1q and the collectins with the potential receptors calreticulin (cClqR/collectin receptor) and megalin. Immunobiology. (1998) 199:208–24. doi: 10.1016/S0171-2985(98)80028-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  QiuYMarquez-CurtisLAJanowska-WieczorekA. Mesenchymal stem cells express the surface receptor calreticulin (cC1qR) and complement C1q chemoattracts them. Blood. (2010) 116:3855–5. doi: 10.1182/blood.V116.21.3855.3855

  • CrossRef
  • Google Scholar

• 143

  HiranoMTotaniKFukudaTGuJSuzukiA. N-Glycoform-dependent interactions of megalin with its ligands. Biochim Biophys Acta (BBA) - Gen Subj. (2017) 1861:3106–18. doi: 10.1016/j.bbagen.2016.10.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144

  HammadRAglanRBMohammedSAAwadEAElsaidMABedairHMet al. Cytotoxic T cell expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) in viral hepatitis C-mediated hepatocellular carcinoma. Int J Mol Sci. (2022) 23. doi: 10.3390/ijms232012541

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  HelouDGQuachCHurrellBPLiXLiMAkbariAet al. LAIR-1 limits macrophage activation in acute inflammatory lung injury. Mucosal Immunol. (2023) 16:788–800. doi: 10.1016/j.mucimm.2023.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  SonMSantiago-SchwarzFAl-AbedYDiamondB. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci U.S.A. (2012) 109:E3160–3167. doi: 10.1073/pnas.1212753109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  SonMDiamondBVolpeBTAranowCBMackayMCSantiago-SchwarzF. Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression. Sci Rep. (2017) 7:270. doi: 10.1038/s41598-017-00290-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148

  CarvalheiroTGarciaSPascoal RamosMIGiovannoneBRadstakeTMarutWet al. Leukocyte associated immunoglobulin like receptor 1 regulation and function on monocytes and dendritic cells during inflammation. Front Immunol. (2020) 11:1793. doi: 10.3389/fimmu.2020.01793

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  HelouDGShafiei-JahaniPHurrellBPPainterJDQuachCHowardEet al. LAIR-1 acts as an immune checkpoint on activated ILC2s and regulates the induction of airway hyperreactivity. J Allergy Clin Immunol. (2022) 149:223–236.e226. doi: 10.1016/j.jaci.2021.05.042

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  MoritaHSaitoHMatsumotoK. Immune checkpoint molecules on ILC2s as potential therapeutic targets for allergic diseases. J Allergy Clin Immunol. (2022) 149:60–2. doi: 10.1016/j.jaci.2021.10.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  KumawatKGeerdinkRJHennusMPRodaMAvan ArkILeusink-MuisTet al. LAIR-1 limits neutrophilic airway inflammation. Front Immunol. (2019) 10:842. doi: 10.3389/fimmu.2019.00842

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152

  ParkCGTakaharaKUmemotoEYashimaYMatsubaraKMatsudaYet al. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int Immunol. (2001) 13:1283–90. doi: 10.1093/intimm/13.10.1283

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153

  KangY-SKimJYBrueningSAPackMCharalambousAPritskerAet al. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc Natl Acad Sci. (2004) 101:215–20. doi: 10.1073/pnas.0307124101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  TakagiHNumazakiMKajiwaraTAbeYIshiiMKatoCet al. Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages. Glycobiology. (2009) 19:258–66. doi: 10.1093/glycob/cwn128

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155

  KawauchiYIgarashiMKojimaN. C-type lectin receptor SIGNR1 expressed on peritoneal phagocytic cells with an immature dendritic cell-like phenotype is involved in uptake of oligomannose-coated liposomes and subsequent cell maturation. Cell Immunol. (2014) 287:121–8. doi: 10.1016/j.cellimm.2014.01.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  ParkJYChoiHJPrabagarMGChoiWSKimSJCheongCet al. The C-type lectin CD209b is expressed on microglia and it mediates the uptake of capsular polysaccharides of Streptococcus pneumoniae. Neurosci Lett. (2009) 450:246–51. doi: 10.1016/j.neulet.2008.11.070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157

  KangY-SDoYLeeH-KParkSHCheongCLynchRMet al. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell. (2006) 125:47–58. doi: 10.1016/j.cell.2006.01.046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  GeijtenbeekTBGrootPCNolteMAvan VlietSJGangaram-PandaySTvan DuijnhovenGCet al. Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens. vivo. Blood. (2002) 100:2908–16. doi: 10.1182/blood-2002-04-1044

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159

  RoozendaalRCarrollMC. Emerging patterns in complement-mediated pathogen recognition. Cell. (2006) 125:29–32. doi: 10.1016/j.cell.2006.03.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  Silva-MartínNBartualSGRamírez-AportelaEChacónPParkCGHermosoJA. Structural basis for selective recognition of endogenous and microbial polysaccharides by macrophage receptor SIGN-R1. Structure. (2014) 22:1595–606. doi: 10.1016/j.str.2014.09.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  PrabagarMGDoYRyuSParkJYChoiHJChoiWSet al. SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen. Cell Death Differentiation. (2013) 20:535–45. doi: 10.1038/cdd.2012.160

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  ParkJYLohSChoEHChoiHJNaTYNemenoJGet al. SIGN-R1 and complement factors are involved in the systemic clearance of radiation-induced apoptotic cells in whole-body irradiated mice. Biochem Biophys Res Commun. (2015) 463:1064–70. doi: 10.1016/j.bbrc.2015.06.059

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163

  PirgovaGChauveauAMacLeanAJCysterJGArnonTI. Marginal zone SIGN-R1⁺ macrophages are essential for the maturation of germinal center B cells in the spleen. Proc Natl Acad Sci. (2020) 117:12295–305. doi: 10.1073/pnas.1921673117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  KoppelEALitjensMvan den BergVCvan KooykYGeijtenbeekTB. Interaction of SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to early IgM responses against Streptococcus pneumoniae. Mol Immunol. (2008) 45:2881–7. doi: 10.1016/j.molimm.2008.01.032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165

  FigueroaJEDensenP. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. (1991) 4:359–95. doi: 10.1128/CMR.4.3.359

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  RossGD. Introduction and history of complement research. In: RossGD, editor. Immunobiology of the Complement System. USA: Academic Press (1986). p. pp 1–19.

  • Google Scholar

• 167

  MarkiewskiMMNilssonBNilsson EkdahlKMollnesTELambrisJD. Complement and coagulation: strangers or partners in crime? Trends Immunol. (2007) 28:184–92. doi: 10.1016/j.it.2007.02.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  MaisonCMVilliersCLColombMG. Proteolysis of C3 on U937 cell plasma membranes. Purification cathepsin G. J Immunol. (1991) 147:921–6. doi: 10.4049/jimmunol.147.3.921

  • CrossRef
  • Google Scholar

• 169

  MatsudaTNagasawaSKoideTKoyamaJ. Limited proteolysis of a chemically modified third component of human complement, C3, by cathepsin G of human leukocytes. J Biochem. (1985) 98:229–36. doi: 10.1093/oxfordjournals.jbchem.a135262

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  LiszewskiMKKolevMLe FriecGLeungMBertramPGFaraAFet al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. (2013) 39:1143–57. doi: 10.1016/j.immuni.2013.10.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  LajoieSWills-KarpM. New twist on an ancient innate immune pathway. Immunity. (2013) 39:1000–2. doi: 10.1016/j.immuni.2013.11.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  YeJYuanKDaiWSunKLiGTanMet al. The mTORC1 signaling modulated by intracellular C3 activation in Paneth cells promotes intestinal epithelial regeneration during acute injury. Int Immunopharmacol. (2019) 67:54–61. doi: 10.1016/j.intimp.2018.12.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  LueschowSRMcElroySJ. The paneth cell: the curator and defender of the immature small intestine. Front Immunol. (2020) 11:587. doi: 10.3389/fimmu.2020.00587

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  OuelletteAJ. Paneth cell alpha-defensins: peptide mediators of innate immunity in the small intestine. Springer Semin Immunopathol. (2005) 27:133–46. doi: 10.1007/s00281-005-0202-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175

  KremlitzkaMColineauLNowackaAAMohlinFCWozniakKBlomAMet al. Alternative translation and retrotranslocation of cytosolic C3 that detects cytoinvasive bacteria. Cell Mol Life Sci. (2022) 79:291. doi: 10.1007/s00018-022-04308-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  KulakKKuskaKColineauLMcKayMMaziarzKSlabyJet al. Intracellular C3 protects β-cells from IL-1β-driven cytotoxicity via interaction with Fyn-related kinase. Proc Natl Acad Sci U.S.A. (2024) 121:e2312621121. doi: 10.1073/pnas.2312621121

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  WelshMWelshCEkmanMDixeliusJHägerkvistRAnnerénCet al. The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity. Biochem J. (2004) 382:261–8. doi: 10.1042/BJ20040285

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  Dos SantosRSMarroquiLGriecoFAMarselliLSuleimanMHenzSRet al. Protective role of complement C3 against cytokine-mediated β-cell apoptosis. Endocrinology. (2017) 158:2503–21. doi: 10.1210/en.2017-00104

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  XuDZhouSLiuYScottALYangJWanF. Complement in breast milk modifies offspring gut microbiota to promote infant health. Cell. (2024) 187:750–763.e720. doi: 10.1016/j.cell.2023.12.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  PapatriantafyllouM. Complement in maternal milk shapes the infant microbiome. Nat Rev Immunol. (2024) 24:159–9. doi: 10.1038/s41577-024-01006-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  MartinUBockDArsenievLTornettaMAAmesRSBautschWet al. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med. (1997) 186:199–207. doi: 10.1084/jem.186.2.199

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  ZwirnerJGötzeOBegemannGKappAKirchhoffKWerfelT. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology. (1999) 97:166–72. doi: 10.1046/j.1365-2567.1999.00764.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  LaumonnierYKarstenCMKöhlJ. Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. Mol Immunol. (2017) 89:44–58. doi: 10.1016/j.molimm.2017.05.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  TschernigTKiafardZDibbertCNeumannDZwirnerJ. Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in rat and murine models of lung inflammation. Exp Toxicologic Pathol. (2007) 58:419–25. doi: 10.1016/j.etp.2007.03.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185

  AsgariELe FriecGYamamotoHPeruchaESacksSSKöhlJet al. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. (2013) 122:3473–81. doi: 10.1182/blood-2013-05-502229

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  MogilenkoDADankoKLarionovaEEShavvaVSKudriavtsevIVNekrasovaEVet al. Differentiation of human macrophages with anaphylatoxin C3a impairs alternative M2 polarization and decreases lipopolysaccharide-induced cytokine secretion. Immunol Cell Biol. (2022) 100:186–204. doi: 10.1111/imcb.12534

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  WeiL-LMaNWuK-YWangJ-XDiaoT-YZhaoS-Jet al. Protective role of C3aR (C3a anaphylatoxin receptor) against atherosclerosis in atherosclerosis-prone mice. Arteriosclerosis Thrombosis Vasc Biol. (2020) 40:2070–83. doi: 10.1161/ATVBAHA.120.314150

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  QuellKMKarstenCMKordowskiAAlmeidaLNBriukhovetskaDWieseAVet al. Monitoring C3aR expression using a floxed tdTomato-C3aR reporter knock-in mouse. J Immunol. (2017) 199:688–706. doi: 10.4049/jimmunol.1700318

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  GugliettaSChiavelliAZagatoEKriegCGandiniSRavendaPSet al. Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat Commun. (2016) 7:11037. doi: 10.1038/ncomms11037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  GasquePSinghraoSKNealJWWangPSayahSFontaineMet al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol. (1998) 160:3543–54. doi: 10.4049/jimmunol.160.7.3543

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191

  CorcoranJANapierBA. C3aR plays both sides in regulating resistance to bacterial infections. PLoS Pathog. (2022) 18:e1010657. doi: 10.1371/journal.ppat.1010657

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  BrennanFHJogiaTGillespieERBlomsterLVLiXXNowlanBet al. Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. JCI Insight. (2019) 4. doi: 10.1172/jci.insight.98254

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  WuMCLBrennanFHLynchJPLMantovaniSPhippsSWetselRAet al. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci. (2013) 110:9439–44. doi: 10.1073/pnas.1218815110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  KirchhoffKWeinmannOZwirnerJBegemannGGötzeOKappAet al. Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology. (2001) 103:210–7. doi: 10.1046/j.1365-2567.2001.01197.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  LiKFazekasovaHWangNSagooPPengQKhamriWet al. Expression of complement components, receptors and regulators by human dendritic cells. Mol Immunol. (2011) 48:1121–7. doi: 10.1016/j.molimm.2011.02.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  PengQLiKAndersonKFarrarCALuBSmithRAGet al. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a–C3aR interaction. Blood. (2008) 111:2452–61. doi: 10.1182/blood-2007-06-095018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  LiKAndersonKJPengQNobleALuBKellyAPet al. Cyclic AMP plays a critical role in C3a-receptor–mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood. (2008) 112:5084–94. doi: 10.1182/blood-2008-05-156646

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  GutzmerRLisewskiMZwirnerJMommertSDieselCWittmannMet al. Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology. (2004) 111:435–43. doi: 10.1111/j.1365-2567.2004.01829.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  PeteringHKöhlJRWeyergrafADulkysYKimmigDSmolarskiRet al. Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a1. J Immunol. (2000) 164:3783–9. doi: 10.4049/jimmunol.164.7.3783

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200

  TakafujiSTadokoroKItoKDahindenCA. Degranulation from human eosinophils stimulated with C3a and C5a. Int Arch Allergy Immunol. (1994) 104 Suppl 1:27–9. doi: 10.1159/000236743

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 201

  DaffernPJPfeiferPHEmberJAHugliTE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med. (1995) 181:2119–27. doi: 10.1084/jem.181.6.2119

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202

  ElsnerJOppermannMCzechWDobosGSchöpfENorgauerJet al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol. (1994) 24:518–22. doi: 10.1002/eji.1830240304

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203

  DahindenCABischoffSCBrunnerTKriegerMTakafujiSde WeckAL. Regulation of mediator release by human basophils: importance of the sequence and time of addition in the combined action of different agonists. Int Arch Allergy Appl Immunol. (1991) 94:161–4. doi: 10.1159/000235350

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204

  KretzschmarTJerominAGietzCBautschWKlosAKöhlJet al. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur J Immunol. (1993) 23:558–61. doi: 10.1002/eji.1830230239

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205

  AliH. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett. (2010) 128:36–45. doi: 10.1016/j.imlet.2009.10.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206

  SoruriAGrigatJKiafardZZwirnerJ. Mast cell activation is characterized by upregulation of a functional anaphylatoxin C5a receptor. BMC Immunol. (2008) 9:29. doi: 10.1186/1471-2172-9-29

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 207

  GuoQSubramanianHGuptaKAliH. Regulation of C3a receptor signaling in human mast cells by G protein coupled receptor kinases. PLoS One. (2011) 6:e22559. doi: 10.1371/journal.pone.0022559

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208

  Elieh Ali KomiDShafaghatFKovanenPTMeriS. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy. (2020) 75:2818–28. doi: 10.1111/all.14413

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209

  LohmanR-JHamidonJKReidRCRowleyJAYauM-KHaliliMAet al. Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nat Commun. (2017) 8:351. doi: 10.1038/s41467-017-00414-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210

  SauterRJSauterMReisESEmschermannFNNordingHEbenhöchSet al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation. (2018) 138:1720–35. doi: 10.1161/CIRCULATIONAHA.118.034600

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211

  PatzeltJMuellerKALBreuningSKarathanosASchleicherRSeizerPet al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis. (2015) 238:289–95. doi: 10.1016/j.atherosclerosis.2014.12.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212

  PolleyMJNachmanRL. Human platelet activation by C3a and C3a des-arg. J Exp Med. (1983) 158:603–15. doi: 10.1084/jem.158.2.603

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 213

  MinXLiuCWeiYWangNYuanGLiuDet al. Expression and regulation of complement receptors by human natural killer cells. Immunobiology. (2014) 219:671–9. doi: 10.1016/j.imbio.2014.03.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214

  NandagopalSLiCGXuYSodjiQHGravesEEGiacciaAJ. C3aR signaling inhibits NK-cell infiltration into the tumor microenvironment in mouse models. Cancer Immunol Res. (2022) 10:245–58. doi: 10.1158/2326-6066.CIR-21-0435

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215

  SodjiQHNambiarDKViswanathanVvon EybenRColburgDBinkleyMSet al. The combination of radiotherapy and complement C3a inhibition potentiates natural killer cell functions against pancreatic cancer. Cancer Res Commun. (2022) 2:725–38. doi: 10.1158/2767-9764.CRC-22-0069

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216

  StrainicMGLiuJHuangDAnFLalliPNMuqimNet al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. (2008) 28:425–35. doi: 10.1016/j.immuni.2008.02.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 217

  GhannamAFauquertJ-LThomasCKemperCDrouetC. Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation. Mol Immunol. (2014) 58:98–107. doi: 10.1016/j.molimm.2013.11.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218

  WerfelTKirchhoffKWittmannMBegemannGKappAHeidenreichFet al. Activated human T lymphocytes express a functional C3a receptor1. J Immunol. (2000) 165:6599–605. doi: 10.4049/jimmunol.165.11.6599

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219

  KwanWHvan der TouwWPaz-ArtalELiMOHeegerPS. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med. (2013) 210:257–68. doi: 10.1084/jem.20121525

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220

  HessCKemperC. Complement-mediated regulation of metabolism and basic cellular processes. Immunity. (2016) 45:240–54. doi: 10.1016/j.immuni.2016.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 221

  NatafSStahelPFDavoustNBarnumSR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci. (1999) 22:397–402. doi: 10.1016/s0166-2236(98)01390-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222

  DavoustNJonesJStahelPFAmesRSBarnumSR. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia. (1999) 26:201–11. doi: 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223

  IschenkoASayahSPatteCAndreevSGasquePSchouftMTet al. Expression of a functional anaphylatoxin C3a receptor by astrocytes. J Neurochem. (1998) 71:2487–96. doi: 10.1046/j.1471-4159.1998.71062487.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 224

  GedamMZhengH. Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer’s disease. Eur J Immunol. (2024) 54:2350815. doi: 10.1002/eji.202350815

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225

  SchraufstatterIUTrieuKSikoraLSriramaraoPDiScipioR. Complement C3a and C5a induce different signal transduction cascades in endothelial cells1. J Immunol. (2002) 169:2102–10. doi: 10.4049/jimmunol.169.4.2102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 226

  SartainSETurnerNAMoakeJL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem. (2018) 293:7195–208. doi: 10.1074/jbc.RA118.002639

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227

  ShivshankarPLiY-DMueller-OrtizSLWetselRA. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells. FASEB J. (2020) 34:7540–60. doi: 10.1096/fj.201902397R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228

  PropsonNERoyERLitvinchukAKöhlJZhengH. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J Clin Invest. (2021) 131. doi: 10.1172/JCI140966

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 229

  WolfHNGuempeleinLSchikoraJPaulyD. C3a Mediates Endothelial Barrier Disruption in Brain-Derived, but Not Retinal, Human Endothelial Cells. Int J Mol Sci. (2024) 25. doi: 10.3390/ijms252011240

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230

  YouDNieKWuXWengMYangLChenYet al. C3a/C3aR synergies with TGF-β to promote epithelial-mesenchymal transition of renal tubular epithelial cells via the activation of the NLRP3 inflammasome. J Transl Med. (2023) 21:904. doi: 10.1186/s12967-023-04764-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231

  IshiiMBeesonGBeesonCRohrerB. Mitochondrial C3a receptor activation in oxidatively stressed epithelial cells reduces mitochondrial respiration and metabolism. Front Immunol. (2021) 12:628062. doi: 10.3389/fimmu.2021.628062

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232

  SchraufstatterIUKhaldoyanidiSKDiScipioRG. Complement activation in the context of stem cells and tissue repair. World J Stem Cells. (2015) 7:1090–108. doi: 10.4252/wjsc.v7.i8.1090

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 233

  RobinsonMJQuastITarlintonDM. Complement-in’ the germinal center response. Nat Immunol. (2021) 22:673–4. doi: 10.1038/s41590-021-00946-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234

  CumpelikAHejaDHuYVaranoGOrdikhaniFRobertoMPet al. Dynamic regulation of B cell complement signaling is integral to germinal center responses. Nat Immunol. (2021) 22:757–68. doi: 10.1038/s41590-021-00926-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 235

  SchanzenbacherJHendrika KählerKMeslerEKleingarnMMarcel KarstenCLeonard SeilerD. The role of C5a receptors in autoimmunity. Immunobiology. (2023) 228:152413. doi: 10.1016/j.imbio.2023.152413

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236

  ZhangKLiG-QHeQ-HLiYTangMZhengQ-Yet al. C5a/C5aR pathway accelerates renal ischemia-reperfusion injury by downregulating PGRN expression. Int Immunopharmacol. (2017) 53:17–23. doi: 10.1016/j.intimp.2017.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 237

  GaoHYanC. New insights for C5a and C5a receptors in sepsis. Front Immunol. (2012) 3. doi: 10.3389/fimmu.2012.00368

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 238

  RiedemannNCGuoRFWardPA. A key role of C5a/C5aR activation for the development of sepsis. J Leukoc Biol. (2003) 74:966–70. doi: 10.1189/jlb.0403137

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 239

  WardPA. The dark side of C5a in sepsis. Nat Rev Immunol. (2004) 4:133–42. doi: 10.1038/nri1269

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 240

  LiRCoulthardLGWuMCTaylorSMWoodruffTM. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. (2013) 27:855–64. doi: 10.1096/fj.12-220509

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 241

  ScolaAMJohswichKOMorganBPKlosAMonkPN. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol. (2009) 46:1149–62. doi: 10.1016/j.molimm.2008.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 242

  CuiWSimaanMLaporteSLodgeRCianfloneK. C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation. Mol Immunol. (2009) 46:3086–98. doi: 10.1016/j.molimm.2009.06.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 243

  TomFQGauvreauDLapointeMLuHPoursharifiPLuoXPet al. Differential chemoattractant response in adipocytes and macrophages to the action of acylation stimulating protein. Eur J Cell Biol. (2013) 92:61–9. doi: 10.1016/j.ejcb.2012.10.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 244

  PoursharifiPLapointeMFisetteALuHRoyCMunkondaMNet al. C5aR and C5L2 act in concert to balance immunometabolism in adipose tissue. Mol Cell Endocrinol. (2014) 382:325–33. doi: 10.1016/j.mce.2013.10.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 245

  CuiWLapointeMGauvreauDKalantDCianfloneK. Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol Immunol. (2009) 46:3207–17. doi: 10.1016/j.molimm.2009.08.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 246

  QuLHJinXLiLMLiSYXieHP. A novel mutation in C5L2 gene was associated with hyperlipidemia and retinitis pigmentosa in a Chinese family. Lipids Health Dis. (2014) 13:75. doi: 10.1186/1476-511X-13-75

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 247

  CainSAMonkPN. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-arg⁷⁴*. J Biol Chem. (2002) 277:7165–9. doi: 10.1074/jbc.C100714200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 248

  OhnoMHirataTEnomotoMArakiTIshimaruHTakahashiTA. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol. (2000) 37:407–12. doi: 10.1016/S0161-5890(00)00067-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 249

  LeeDKGeorgeSRChengRNguyenTLiuYBrownMet al. Identification of four novel human G protein-coupled receptors expressed in the brain. Brain Res Mol Brain Res. (2001) 86:13–22. doi: 10.1016/S0169-328X(00)00242-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 250

  GaoHNeffTAGuoRFSpeyerCLSarmaJVTomlinsSet al. Evidence for a functional role of the second C5a receptor C5L2. FASEB J. (2005) 19:1003–5. doi: 10.1096/fj.04-3424fje

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 251

  ChenNJMirtsosCSuhDLuYCLinWJMcKerlieCet al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. (2007) 446:203–7. doi: 10.1038/nature05559

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 252

  KalantDMacLarenRCuiWSamantaRMonkPNLaporteSAet al. C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem. (2005) 280:23936–44. doi: 10.1074/jbc.M406921200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 253

  LeeHWhitfeldPLMackayCR. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol. (2008) 86:153–60. doi: 10.1038/sj.icb.7100166

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 254

  KarstenCMWieseAVMeyFFiggeJWoodruffTMReuterTet al. Monitoring C5aR2 expression using a floxed tdTomato-C5aR2 knock-in mouse. J Immunol. (2017) 199:3234–48. doi: 10.4049/jimmunol.1700710

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 255

  KarstenCMLaumonnierYEurichBEnderFBrökerKRoySet al. Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse. J Immunol. (2015) 194:1841–55. doi: 10.4049/jimmunol.1401401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 256

  SeilerDLKählerKHKleingarnMSadikCDBieberKKöhlJet al. The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita. Front Immunol. (2023) 14:1197709. doi: 10.3389/fimmu.2023.1197709

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 257

  ZaalAvan HamSMTen BrinkeA. Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2. Immunol Lett. (2019) 209:45–52. doi: 10.1016/j.imlet.2019.03.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 258

  ZaalADiekerMOudenampsenMTurksmaAWLissenberg-ThunnissenSNWoutersDet al. Anaphylatoxin C5a regulates 6-sulfo-lacNAc dendritic cell function in human through crosstalk with toll-like receptor-induced CREB signaling. Front Immunol. (2017) 8. doi: 10.3389/fimmu.2017.00818

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 259

  GerardNPHodgesMKDrazenJMWellerPFGerardC. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem. (1989) 264:1760–6. doi: 10.1016/S0021-9258(18)94252-3

  • CrossRef
  • Google Scholar

• 260

  DiScipioRGDaffernPJJagelsMABroideDHSriramaraoP. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo1. J Immunol. (1999) 162:1127–36. doi: 10.4049/jimmunol.162.2.1127

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 261

  ElsnerJOppermannMKappA. Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Eur J Immunol. (1996) 26:1560–4. doi: 10.1002/eji.1830260723

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 262

  BambergCEMackayCRLeeHZahraDJacksonJLimYSet al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction*. J Biol Chem. (2010) 285:7633–44. doi: 10.1074/jbc.M109.092106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 263

  ZhangXSchmuddeILaumonnierYPandeyMKClarkJRKönigPet al. A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol. (2010) 185:6741–52. doi: 10.4049/jimmunol.1000892

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 264

  FürederWAgisHWillheimMBanklHCMaierUKishiKet al. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol. (1995) 155:3152–60. doi: 10.4049/jimmunol.155.6.3152

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 265

  SchulmanESPostTJHensonPMGiclasPC. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest. (1988) 81:918–23. doi: 10.1172/JCI113403

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 266

  EgliteSPlüssKDahindenCA. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils. J Immunol. (2000) 165:2183–9. doi: 10.4049/jimmunol.165.4.2183

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 267

  NilssonGJohnellMHammerCHTiffanyHLNilssonKMetcalfeDDet al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol. (1996) 157:1693–8. doi: 10.4049/jimmunol.157.4.1693

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 268

  HartmannKHenzBMKrüger-KrasagakesSKöhlJBurgerRGuhlSet al. C3a and C5a stimulate chemotaxis of human mast cells. Blood. (1997) 89:2863–70. doi: 10.1182/blood.V89.8.2863

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 269

  el-LatiSGDahindenCAChurchMK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol. (1994) 102:803–6. doi: 10.1111/1523-1747.ep12378589

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 270

  PundirPMacDonaldCAKulkaM. The novel receptor C5aR2 is required for C5a-mediated human mast cell adhesion, migration, and proinflammatory mediator production. J Immunol. (2015) 195:2774–87. doi: 10.4049/jimmunol.1401348

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 271

  PundirPKulkaM. The seven-transmembrane receptor, C5L2, is a stimulatory receptor on human mast cells. Allergy Asthma Clin Immunol. (2010) 6:P25. doi: 10.1186/1710-1492-6-S2-P25

  • CrossRef
  • Google Scholar

• 272

  PundirPKulkaM. Functional expression of the novel C5a receptor C5L2 in human mast cells. J Allergy Clin Immunol. (2013) 131:AB239.

  • Google Scholar

• 273

  NordingHBaronLHaberthürDEmschermannFMezgerMSauterMet al. The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets. Nat Commun. (2021) 12:3352. doi: 10.1038/s41467-021-23499-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 274

  MeuerSEckerUHaddingUBitter-SuermannD. Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J Immunol. (1981) 126:1506–9. doi: 10.4049/jimmunol.126.4.1506

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 275

  MatsumotoKYasuokaHYoshimotoKSuzukiKTakeuchiT. Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis. Sci Rep. (2021) 11:222. doi: 10.1038/s41598-020-80685-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 276

  ApostolidisSASarkarAGianniniHMGoelRRMathewDSuzukiAet al. Signaling through fcγRIIA and the C5a-C5aR pathway mediate platelet hyperactivation in COVID-19. Front Immunol. (2022) 13:834988. doi: 10.3389/fimmu.2022.834988

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 277

  AielloSGastoldiSGalbuseraMRuggenentiPPortalupiVRotaSet al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv. (2022) 6:866–81. doi: 10.1182/bloodadvances.2021005246

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 278

  BoeckelHKarstenCMGöpelWHertingERuppJHärtelCet al. Increased expression of anaphylatoxin C5a-receptor-1 in neutrophils and natural killer cells of preterm infants. Int J Mol Sci. (2023) 24. doi: 10.3390/ijms241210321

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 279

  FusakioMEMohammedJPLaumonnierYHoebeKKöhlJMattnerJ. C5a regulates NKT and NK cell functions in sepsis. J Immunol. (2011) 187:5805–12. doi: 10.4049/jimmunol.1100338

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 280

  QingXKooGCSalmonJE. Complement regulates conventional DC-mediated NK-cell activation by inducing TGF-β1 in Gr-1+ myeloid cells. Eur J Immunol. (2012) 42:1723–34. doi: 10.1002/eji.201142290

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 281

  HanGGengSLiYChenGWangRLiXet al. γδT-cell function in sepsis is modulated by C5a receptor signalling. Immunology. (2011) 133:340–9. doi: 10.1111/j.1365-2567.2011.03445.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 282

  ZhengQYXuFYangYSunDDZhongYWuSet al. C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from γδ-T cells. FASEB J. (2020) 34:10590–604. doi: 10.1096/fj.202000384R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 283

  LalliPNStrainicMGYangMLinFMedofMEHeegerPS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. (2008) 112:1759–66. doi: 10.1182/blood-2008-04-151068

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 284

  NatafSDavoustNAmesRSBarnumSR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol. (1999) 162:4018–23. doi: 10.4049/jimmunol.162.7.4018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 285

  KimAHJDimitriouIDHollandMCHMastellosDMuellerYMAltmanJDet al. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses1. J Immunol. (2004) 173:2524–9. doi: 10.4049/jimmunol.173.4.2524

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 286

  LuanXLeiTFangJLiuXFuHLiYet al. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity. Mol Ther. (2024) 32:469–89. doi: 10.1016/j.ymthe.2023.12.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 287

  AgerRRFonsecaMIChuSHSandersonSDTaylorSMWoodruffTMet al. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer’s disease. J Neurochem. (2010) 113:389–401. doi: 10.1111/j.1471-4159.2010.06595.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 288

  GriffinRSCostiganMBrennerGJMaCHScholzJMossAet al. Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci. (2007) 27:8699–708. doi: 10.1523/JNEUROSCI.2018-07.2007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 289

  PeknaMPeknyM. The complement system: A powerful modulator and effector of astrocyte function in the healthy and diseased central nervous system. Cells. (2021) 10. doi: 10.3390/cells10071812

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 290

  BrennanFHGordonRLaoHWBigginsPJTaylorSMFranklinRJet al. The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury. J Neurosci. (2015) 35:6517–31. doi: 10.1523/JNEUROSCI.5218-14.2015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 291

  SchartzNDLiangHYCarvalhoKChuS-HMendoza-ArvillaAPetriskoTJet al. C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer’s disease mouse model. Nat Commun. (2024) 15:7028. doi: 10.1038/s41467-024-51163-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 292

  BigginsPJCBrennanFHTaylorSMWoodruffTMRuitenbergMJ. The alternative receptor for complement component 5a, C5aR2, conveys neuroprotection in traumatic spinal cord injury. J Neurotrauma. (2017) 34:2075–85. doi: 10.1089/neu.2016.4701

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 293

  CarvalhoKSchartzNDBalderrama-GutierrezGLiangHYChuSHSelvanPet al. Modulation of C5a-C5aR1 signaling alters the dynamics of AD progression. J Neuroinflamm. (2022) 19:178. doi: 10.1186/s12974-022-02539-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 294

  LaudesIJChuJCHuber-LangMGuoRFRiedemannNCSarmaJVet al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol. (2002) 169:5962–70. doi: 10.4049/jimmunol.169.10.5962

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 295

  VijayanSAsareYGrommesJSoehnleinOLutgensEShagdarsurenGet al. High expression of C5L2 correlates with high proinflammatory cytokine expression in advanced human atherosclerotic plaques. Am J Pathol. (2014) 184:2123–33. doi: 10.1016/j.ajpath.2014.04.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 296

  MonkPNScolaAMMadalaPFairlieDP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. (2007) 152:429–48. doi: 10.1038/sj.bjp.0707332

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 297

  DingPXuYLiLLvXLiLChenJet al. Intracellular complement C5a/C5aR1 stabilizes β-catenin to promote colorectal tumorigenesis. Cell Rep. (2022) 39:110851. doi: 10.1016/j.celrep.2022.110851

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 298

  BeachCMacLeanDMajorovaDMelemenidisSNambiarDKKimRKet al. Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments. bioRxiv. (2023). doi: 10.1101/2023.01.10.521547

  • CrossRef
  • Google Scholar

• 299

  IshiiMRohrerB. Anaphylatoxin C5a receptor signaling induces mitochondrial fusion and sensitizes retinal pigment epithelial cells to oxidative stress. Biochim Biophys Acta (BBA) - Gen Subj. (2023) 1867:130374. doi: 10.1016/j.bbagen.2023.130374

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 300

  JohswichKMartinMThalmannJRheinheimerCMonkPNKlosA. Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J Biol Chem. (2006) 281:39088–95. doi: 10.1074/jbc.M609734200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 301

  OglesbyTJLongwithJEHuettnerPC. Human complement regulator expression by the normal female reproductive tract. Anat Rec. (1996) 246:78–86. doi: 10.1002/(SICI)1097-0185(199609)246:1<78::AID-AR9>3.0.CO;2-B

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 302

  IborraAMayorgaMLlobetNMartínezP. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells. Cell Immunol. (2003) 223:46–51. doi: 10.1016/S0008-8749(03)00127-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 303

  FénichelPCervoniFDonzeauMHsiBL. Expression and role of complement regulatory proteins on human gametes and pre-implantation embryos. Contracept Fertil Sex. (1995) 23:576–80.

  • Pubmed Abstract
  • Google Scholar

• 304

  FenichelPDonzeauMCervoniFMenezoYHsiBL. Expression of complement regulatory proteins on human eggs and preimplantation embryos. Am J Reprod Immunol. (1995) 33:155–64. doi: 10.1111/j.1600-0897.1995.tb00879.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 305

  TaylorCTJohnsonPM. Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes. Mol Hum Reprod. (1996) 2:52–9. doi: 10.1093/molehr/2.1.52

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 306

  ReichhardtMPLundinKLokkiAIRecherGVuoristoSKatayamaSet al. Complement in human pre-implantation embryos: attack and defense. Front Immunol. (2019) 10:2234. doi: 10.3389/fimmu.2019.02234

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 307

  JiangHPillaiS. Complement regulatory proteins on the sperm surface: relevance to sperm motility. Am J Reprod Immunol. (1998) 39:243–8. doi: 10.1111/j.1600-0897.1998.tb00360.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 308

  CervoniFOglesbyTJAdamsEMMilesifluetCNickellsMFenichelPet al. Identification and characterization of membrane cofactor protein of human spermatozoa. J Immunol. (1992) 148:1431–7. doi: 10.4049/jimmunol.148.5.1431

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 309

  CummersonJAFlanaganBFSpillerDGJohnsonPM. The complement regulatory proteins CD55 (decay accelerating factor) and CD59 are expressed on the inner acrosomal membrane of human spermatozoa as well as CD46 (membrane cofactor protein). Immunology. (2006) 118:333–42. doi: 10.1111/j.1365-2567.2006.02374.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 310

  D’CruzOJHaasGGJr. The expression of the complement regulators CD46, CD55, and CD59 by human sperm does not protect them from antisperm antibody- and complement-mediated immune injury. Fertil Steril. (1993) 59:876–84. doi: 10.1016/S0015-0282(16)55875-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 311

  BronsonRBronsonSOulaLZhangWGhebrehiwetB. Detection of complement C1q receptors on human spermatozoa. J Reprod Immunol. (1998) 38:1–14. doi: 10.1016/S0165-0378(98)00006-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 312

  GraceKSBronsonRAGhebrehiwetB. Surface Expression of Complement Receptor gC1q-R/p33 Is Increased on the Plasma Membrane of Human Spermatozoa after Capacitation1. Biol Reprod. (2002) 66:823–9. doi: 10.1095/biolreprod66.3.823

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 313

  AndersonDJAbbottAFJackRM. The role of complement component C3b and its receptors in sperm-oocyte interaction. Proc Natl Acad Sci U.S.A. (1993) 90:10051–5. doi: 10.1073/pnas.90.21.10051

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 314

  Riley-VargasRCLanzendorfSAtkinsonJP. Targeted and restricted complement activation on acrosome-reacted spermatozoa. J Clin Invest. (2005) 115:1241–9. doi: 10.1172/JCI23213

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 315

  BullaRBossiFAgostinisCRadilloOColomboFDe SetaFet al. Complement production by trophoblast cells at the feto-maternal interface. J Reprod Immunol. (2009) 82:119–25. doi: 10.1016/j.jri.2009.06.124

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 316

  HannaJWaldOGoldman-WohlDPrusDMarkelGGazitRet al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood. (2003) 102:1569–77. doi: 10.1182/blood-2003-02-0517

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 317

  DrakePMGunnMDCharoIFTsouCLZhouYHuangLet al. Human placental cytotrophoblasts attract monocytes and CD56(bright) natural killer cells via the actions of monocyte inflammatory protein 1alpha. J Exp Med. (2001) 193:1199–212. doi: 10.1084/jem.193.10.1199

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 318

  KoopmanLAKopcowHDRybalovBBoysonJEOrangeJSSchatzFet al. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med. (2003) 198:1201–12. doi: 10.1084/jem.20030305

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 319

  PijnenborgRVercruysseLHanssensM. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. (2006) 27:939–58. doi: 10.1016/j.placenta.2005.12.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 320

  CharriautCSenikAKolbJPBarelMFradeR. Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment. Proc Natl Acad Sci U.S.A. (1982) 79:6003–7.

  • Pubmed Abstract
  • Google Scholar

• 321

  WangSYVeeramaniSRacilaECagleyJFritzingerDCVogelCWet al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. (2009) 114:5322–30. doi: 10.1182/blood-2009-01-200469

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 322

  WangSYRacilaETaylorRPWeinerGJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. (2008) 111:1456–63. doi: 10.1182/blood-2007-02-074716

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 323

  HannaJGoldman-WohlDHamaniYAvrahamIGreenfieldCNatanson-YaronSet al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. (2006) 12:1065–74. doi: 10.1038/nm1452

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 324

  KarimiKArckPC. Natural Killer cells: keepers of pregnancy in the turnstile of the environment. Brain Behav Immun. (2010) 24:339–47. doi: 10.1016/j.bbi.2009.09.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 325

  KopcowHDAllanDSChenXRybalovBAndzelmMMGeBet al. Human decidual NK cells form immature activating synapses and are not cytotoxic. Proc Natl Acad Sci U.S.A. (2005) 102:15563–8. doi: 10.1073/pnas.0507835102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 326

  AgostinisCBullaRTripodoCGismondiAStabileHBossiFet al. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol. (2010) 185:4420–9. doi: 10.4049/jimmunol.0903215

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 327

  AgostinisCMangognaABalduitAKishoreUBullaR. A non-redundant role of complement protein C1q in normal and adverse pregnancy. Explor Immunol. (2022) 2:622–36. doi: 10.37349/ei

  • CrossRef
  • Google Scholar

• 328

  E DaviesJPollheimerJYongHEKokkinosMIKalionisBKnöflerMet al. Epithelial-mesenchymal transition during extravillous trophoblast differentiation. Cell Adh Migr. (2016) 10:310–21. doi: 10.1080/19336918.2016.1170258

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 329

  TangZLuBHatchESacksSHSheerinNS. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol. (2009) 20:593–603. doi: 10.1681/ASN.2008040434

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 330

  OtsukiTFukudaNChenLTsunemiAAbeM. Twist-related protein 1 induces epithelial-mesenchymal transition and renal fibrosis through the upregulation of complement 3. PLoS One. (2022) 17:e0272917. doi: 10.1371/journal.pone.0272917

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 331

  ChoMSRupaimooleRChoiH-JNohKChenJHuQet al. Complement component 3 is regulated by TWIST1 and mediates epithelial–mesenchymal transition. J Immunol. (2016) 196:1412–8. doi: 10.4049/jimmunol.1501886

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 332

  SoundararajanRRaoAJ. Trophoblast ‘pseudo-tumorigenesis’: significance and contributory factors. Reprod Biol Endocrinol. (2004) 2:15. doi: 10.1186/1477-7827-2-15

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 333

  CarvajalLGutiérrezJMorselliELeivaA. Autophagy process in trophoblast cells invasion and differentiation: similitude and differences with cancer cells. Front Oncol. (2021) 11. doi: 10.3389/fonc.2021.637594

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 334

  FerrettiCBruniLDangles-MarieVPeckingAPBelletD. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. (2006) 13:121–41. doi: 10.1093/humupd/dml048

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 335

  RichaniKSotoERomeroREspinozaJChaiworapongsaTNienJKet al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. (2005) 17:239–45. doi: 10.1080/14767050500072722

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 336

  DerzsyZProhászkaZRigóJJr.FüstGMolvarecA. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. (2010) 47:1500–6. doi: 10.1016/j.molimm.2010.01.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 337

  AbramsonSBBuyonJP. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol. (1992) 28:183–7. doi: 10.1111/j.1600-0897.1992.tb00787.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 338

  SotoERomeroRRichaniKEspinozaJNienJKChaiworapongsaTet al. Anaphylatoxins in preterm and term labor. J Perinat Med. (2005) 33:306–13. doi: 10.1515/JPM.2005.051

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 339

  LynchAMGibbsRSMurphyJRGiclasPCSalmonJEHolersVM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. (2011) 117:75–83. doi: 10.1097/AOG.0b013e3181fc3afa

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 340

  HeYDXuBNSongDWangYQYuFChenQet al. Normal range of complement components during pregnancy: A prospective study. Am J Reprod Immunol. (2020) 83:e13202. doi: 10.1111/aji.13202

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 341

  RamanjaneyaMDibounIRizwanaNDajaniYAhmedLButlerAEet al. Elevated adipsin and reduced C5a levels in the maternal serum and follicular fluid during implantation are associated with successful pregnancy in obese women. Front Endocrinol (Lausanne). (2022) 13:918320. doi: 10.3389/fendo.2022.918320

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 342

  LiuMLuoXXuQYuHGaoLZhouRet al. Adipsin of the alternative complement pathway is a potential predictor for preeclampsia in early pregnancy. Front Immunol. (2021) 12:702385. doi: 10.3389/fimmu.2021.702385

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 343

  PovedaNEGarcésMFRuiz-LinaresCEVarónDValderramaSSanchezEet al. Serum adipsin levels throughout normal pregnancy and preeclampsia. Sci Rep. (2016) 6:20073. doi: 10.1038/srep20073

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 344

  RosenBSCookKSYaglomJGrovesDLVolanakisJEDammDet al. Adipsin and complement factor D activity: an immune-related defect in obesity. Science. (1989) 244:1483–7. doi: 10.1126/science.2734615

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 345

  XuYMaMIppolitoGCSchroederHWJr.CarrollMCVolanakisJE. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U.S.A. (2001) 98:14577–82. doi: 10.1073/pnas.261428398

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 346

  MilekMMoullaYKernMStrohCDietrichASchönMRet al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci. (2022) 23. doi: 10.3390/ijms23042222

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 347

  LoJCLjubicicSLeibigerBKernMLeibigerIBMoedeTet al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. (2014) 158:41–53. doi: 10.1016/j.cell.2014.06.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 348

  DareAChenS-Y. Adipsin in the pathogenesis of cardiovascular diseases. Vasc Pharmacol. (2024) 154:107270. doi: 10.1016/j.vph.2023.107270

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 349

  CsukaDMolvarecADerzsyZVargaLFüstGRigóJJr.et al. Functional analysis of the mannose-binding lectin complement pathway in normal pregnancy and preeclampsia. J Reprod Immunol. (2010) 87:90–6. doi: 10.1016/j.jri.2010.07.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 350

  LynchAMWagnerBDGiclasPCWestNAGibbsRSHolersVM. The relationship of longitudinal levels of complement bb during pregnancy with preeclampsia. Am J Reprod Immunol. (2016) 75:104–11. doi: 10.1111/aji.12439

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 351

  RegalJFGilbertJSBurwickRM. The complement system and adverse pregnancy outcomes. Mol Immunol. (2015) 67:56–70. doi: 10.1016/j.molimm.2015.02.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 352

  DennyKJWoodruffTMTaylorSMCallawayLK. Complement in pregnancy: a delicate balance. Am J Reprod Immunol. (2013) 69:3–11. doi: 10.1111/aji.12000

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 353

  Alonso-VenturaVLiYPasupuletiVRomanYMHernandezAVPérez-LópezFR. Effects of preeclampsia and eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis. Metabolism. (2020) 102:154012. doi: 10.1016/j.metabol.2019.154012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 354

  PerryHKhalilAThilaganathanB. Preeclampsia and the cardiovascular system: An update. Trends Cardiovasc Med. (2018) 28:505–13. doi: 10.1016/j.tcm.2018.04.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 355

  RobillardPYDekkerGChaouatGSciosciaMIacobelliSHulseyTC. Historical evolution of ideas on eclampsia/preeclampsia: A proposed optimistic view of preeclampsia. J Reprod Immunol. (2017) 123:72–7. doi: 10.1016/j.jri.2017.09.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 356

  Garrido-GómezTCastillo-MarcoNCorderoTSimónC. Decidualization resistance in the origin of preeclampsia. Am J Obstet Gynecol. (2022) 226:S886–s894. doi: 10.1016/j.ajog.2020.09.039

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 357

  LaiJSyngelakiANicolaidesKHvon DadelszenPMageeLA. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. Am J Obstetrics Gynecology. (2021) 224:518.e511–518.e511. doi: 10.1016/j.ajog.2020.11.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 358

  GhulmiyyahLSibaiB. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. (2012) 36:56–9. doi: 10.1053/j.semperi.2011.09.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 359

  JungERomeroRYeoLGomez-LopezNChaemsaithongPJaovisidhaAet al. The etiology of preeclampsia. Am J Obstet Gynecol. (2022) 226:S844–s866. doi: 10.1016/j.ajog.2021.11.1356

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 360

  FisherSJ. Why is placentation abnormal in preeclampsia? Am J Obstetrics Gynecology. (2015) 213:S115–22. doi: 10.1016/j.ajog.2015.08.042

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 361

  ErezORomeroRJungEChaemsaithongPBoscoMSuksaiMet al. Preeclampsia and eclampsia: the conceptual evolution of a syndrome. Am J Obstet Gynecol. (2022) 226:S786–s803. doi: 10.1016/j.ajog.2021.12.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 362

  KumarV. Introductory chapter: macrophages – more than sentinel innate immune cells. In: KumarV, editor. Macrophages - Celebrating 140 Years of Discovery. IntechOpen, Rijeka (2022). doi: 10.5772/intechopen.109647

  • CrossRef
  • Google Scholar

• 363

  DekkerGASibaiBM. The immunology of preeclampsia. Semin Perinatol. (1999) 23:24–33. doi: 10.1016/S0146-0005(99)80057-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 364

  RedmanCWSargentIL. Immunology of pre-eclampsia. Am J Reprod Immunol. (2010) 63:534–43. doi: 10.1111/j.1600-0897.2010.00831.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 365

  CollierAYModestAMAguayoRABondzieEAPatelSHackerMRet al. Altered cytokine production in human intervillous blood T cells in preeclampsia. Reprod Sci. (2023) 30:2655–64. doi: 10.1007/s43032-023-01165-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 366

  Darmochwal-KolarzDKludka-SternikMTabarkiewiczJKolarzBRolinskiJLeszczynska-GorzelakBet al. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Reprod Immunol. (2012) 93:75–81. doi: 10.1016/j.jri.2012.01.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 367

  StefańskaKKurkowiakMPiekarskaKChruścielEZamkowskaDJassem-BobowiczJet al. High maternal-fetal HLA eplet compatibility is associated with severe manifestation of preeclampsia. Front Immunol. (2023) 14:1272021. doi: 10.3389/fimmu.2023.1272021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 368

  van BentemKBosMvan der KeurCBrand-SchaafSHHaasnootGWRoelenDLet al. The development of preeclampsia in oocyte donation pregnancies is related to the number of fetal-maternal HLA class II mismatches. J Reprod Immunol. (2020) 137:103074. doi: 10.1016/j.jri.2019.103074

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 369

  BoulangerHBounanSMahdhiADrouinDAhriz-SaksiSGuimiotFet al. Immunologic aspects of preeclampsia. AJOG Global Rep. (2024) 4:100321. doi: 10.1016/j.xagr.2024.100321

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 370

  BorzychowskiAMSargentILRedmanCW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. (2006) 11:309–16. doi: 10.1016/j.siny.2006.04.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 371

  RammaWAhmedA. Is inflammation the cause of pre-eclampsia? Biochem Soc Trans. (2011) 39:1619–27. doi: 10.1042/BST20110672

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 372

  MarkiewskiMMLambrisJD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. (2007) 171:715–27. doi: 10.2353/ajpath.2007.070166

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 373

  RuanC-CGaoP-J. Role of complement-related inflammation and vascular dysfunction in hypertension. Hypertension. (2019) 73:965–71. doi: 10.1161/HYPERTENSIONAHA.118.11210

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 374

  BlakeyHSunRXieLRussellRSarweenNHodsonJet al. Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue. Pregnancy Hypertension. (2023) 32:43–9. doi: 10.1016/j.preghy.2023.04.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 375

  VelickovicIDalloulMWongKABakareOSchweisFGaralaMet al. Complement factor B activation in patients with preeclampsia. J Reprod Immunol. (2015) 109:94–100. doi: 10.1016/j.jri.2014.12.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 376

  ThanNGRomeroRErezOKusanovicJPTarcaALEdwinSSet al. A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia. Am J Reprod Immunol. (2008) 60:333–45. doi: 10.1111/j.1600-0897.2008.00631.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 377

  JohnsonJDLouisJM. Does race or ethnicity play a role in the origin, pathophysiology, and outcomes of preeclampsia? An expert review of the literature. Am J Obstetrics Gynecology. (2022) 226:S876–85. doi: 10.1016/j.ajog.2020.07.038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 378

  LynchAMMurphyJRByersTGibbsRSNevilleMCGiclasPCet al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. (2008) 198:385.e381–389. doi: 10.1016/j.ajog.2007.10.793

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 379

  JiaKMaLWuSYangW. Serum levels of complement factors C1q, bb, and H in normal pregnancy and severe pre-eclampsia. Med Sci Monit. (2019) 25:7087–93. doi: 10.12659/MSM.915777

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 380

  HeYXuBSongDYuFChenQZhaoM. Expression of the complement system’s activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol. (2016) 76:205–11. doi: 10.1111/aji.12541

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 381

  YeYKongYZhangY. Complement split products C3a/C5a and receptors: are they regulated by circulating angiotensin II type 1 receptor autoantibody in severe preeclampsia? Gynecol Obstet Invest. (2016) 81:28–33. doi: 10.1159/000440651

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 382

  HeYXuBSongDYuFChenQZhaoM. Correlations between complement system’s activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia. Hypertens Pregnancy. (2016) 35:499–509. doi: 10.1080/10641955.2016.1190845

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 383

  LimRLappasM. Decreased expression of complement 3a receptor (C3aR) in human placentas from severe preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol. (2012) 165:194–8. doi: 10.1016/j.ejogrb.2012.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 384

  LaMarcaBWallaceKGrangerJ. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol. (2011) 11:175–9. doi: 10.1016/j.coph.2011.01.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 385

  HerseFLaMarcaB. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol. (2013) 69:413–8. doi: 10.1111/aji.12072

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 386

  PalmerKRTongSKaitu’u-LinoTJ. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Mol Hum Reprod. (2017) 23:69–78. doi: 10.1093/molehr/gaw077

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 387

  MaynardSEMinJYMerchanJLimKHLiJMondalSet al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. (2003) 111:649–58. doi: 10.1172/JCI17189

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 388

  PianiFTossettaGFantoneSAgostinisCDi SimoneNMandalàMet al. First trimester CD93 as a novel marker of preeclampsia and its complications: A pilot study. High Blood Pressure Cardiovasc Prev. (2023) 30:591–4. doi: 10.1007/s40292-023-00608-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 389

  Becerra-MojicaCHMora-GuevaraEParra-SaavedraMAMartínez-VegaRADíaz-MartínezLARincón-OrozcoB. Low levels of complement factor H in the first trimester of pregnancy are associated with spontaneous preterm birth. Int J Mol Sci. (2024) 25. doi: 10.3390/ijms251910549

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 390

  LokkiAIRenZTriebwasserMDalyEPerolaMAuroKet al. Identification of complement factor H variants that predispose to pre-eclampsia: A genetic and functional study. Bjog. (2023) 130:1473–82. doi: 10.1111/1471-0528.17529

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 391

  JääskeläinenTHeinonenSKajantieEKereJKivinenKPoutaAet al. Cohort profile: the finnish genetics of pre-eclampsia consortium (FINNPEC). BMJ Open. (2016) 6:e013148. doi: 10.1136/bmjopen-2016-013148

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 392

  DijkstraDJLokkiAIGiermanLMBorggrevenNVvan der KeurCEikmansMet al. Circulating levels of anti-C1q and anti-factor H autoantibodies and their targets in normal pregnancy and preeclampsia. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.842451

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 393

  YasminHAgostinisCToffoliMRoyTPegoraroSBalduitAet al. Protective role of complement factor H against the development of preeclampsia. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1351898

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 394

  SalmonJEHeuserCTriebwasserMLiszewskiMKKavanaghDRoumeninaLet al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. (2011) 8:e1001013. doi: 10.1371/journal.pmed.1001013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 395

  BalduitAAgostinisCMangognaAZitoGStampalijaTRicciGet al. Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities. Front Immunol. (2024) 15:1419540. doi: 10.3389/fimmu.2024.1419540

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 396

  LokkiAITeiriläLTriebwasserMDalyEBhattacharjeeAUotilaLet al. Dysfunction of complement receptors CR3 (CD11b/18) and CR4 (CD11c/18) in pre-eclampsia: a genetic and functional study. Bjog. (2021) 128:1282–91. doi: 10.1111/1471-0528.16660

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 397

  BurwickRM. Complement receptors in pre-eclampsia: cleaning up placental debris. Bjog. (2021) 128:1292. doi: 10.1111/1471-0528.16664

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 398

  LokkiAITriebwasserMDalyEKurkiMIPerolaMAuroKet al. Understanding rare genetic variants within the terminal pathway of complement system in preeclampsia. Genes Immun. (2025) 26:22–6. doi: 10.1038/s41435-024-00310-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 399

  LarsenJBAndersenASHvasCLThielSLassenMRHvasAMet al. Lectin pathway proteins of the complement system in normotensive pregnancy and pre-eclampsia. Am J Reprod Immunol. (2019) 81:e13092. doi: 10.1111/aji.13092

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 400

  HalmosARigóJJr.SzijártóJFüstGProhászkaZMolvarecA. Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia. Clin Exp Immunol. (2012) 169:49–56. doi: 10.1111/j.1365-2249.2012.04590.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 401

  SzillerIBabulaOHupucziPNagyBRigóBSzabóGet al. Mannose-binding lectin (MBL) codon 54 gene polymorphism protects against development of pre-eclampsia, HELLP syndrome and pre-eclampsia-associated intrauterine growth restriction. Mol Hum Reprod. (2007) 13:281–5. doi: 10.1093/molehr/gam003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 402

  van de GeijnFEDolhainRJvan RijsWHazesJMde GrootCJ. Mannose-binding lectin genotypes and pre-eclampsia: a case-control study. Hum Immunol. (2007) 68:888–93. doi: 10.1016/j.humimm.2007.10.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 403

  BanadakoppaMVidaeffACYallampalliURaminSMBelfortMAYallampalliC. Complement split products in amniotic fluid in pregnancies subsequently developing early-onset preeclampsia. Dis Markers. (2015) 2015:263109. doi: 10.1155/2015/263109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 404

  HaegerMBengtsonAKarlssonKHeidemanM. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. Obstet Gynecol. (1989) 73:551–6.

  • Pubmed Abstract
  • Google Scholar

• 405

  GusehSHFeinbergBBDawoodHYYamamotoHSFichorovaRNBurwickRM. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am J Reprod Immunol. (2015) 73:437–44. doi: 10.1111/aji.12349

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 406

  BurwickRMFichorovaRNDawoodHYYamamotoHSFeinbergBB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. (2013) 62:1040–5. doi: 10.1161/HYPERTENSIONAHA.113.01420

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 407

  BurwickRMVelásquezJAValenciaCMGutiérrez-MarínJEdna-EstradaFSilvaJLet al. Terminal complement activation in preeclampsia. Obstet Gynecol. (2018) 132:1477–85. doi: 10.1097/AOG.0000000000002980

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 408

  BuurmaACohenDVeraarKSchonkerenDClaasFHBruijnJAet al. Preeclampsia is characterized by placental complement dysregulation. Hypertension. (2012) 60:1332–7. doi: 10.1161/HYPERTENSIONAHA.112.194324

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 409

  LokkiAIHeikkinen-ElorantaJJarvaHSaistoTLokkiMLLaivuoriHet al. Complement activation and regulation in preeclamptic placenta. Front Immunol. (2014) 5:312. doi: 10.3389/fimmu.2014.00312

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 410

  Yonekura CollierARZsengellerZPerniconeESalahuddinSKhankinEVKarumanchiSA. Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertens Pregnancy. (2019) 38:193–9. doi: 10.1080/10641955.2019.1640725

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 411

  HolmesCHSimpsonKLWainwrightSDTateCGHoulihanJMSawyerIHet al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol. (1990) 144:3099–105. doi: 10.4049/jimmunol.144.8.3099

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 412

  HolmesCHSimpsonKLOkadaHOkadaNWainwrightSDPurcellDFet al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol. (1992) 22:1579–85. doi: 10.1002/eji.1830220635

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 413

  MaYKongLRGeQLuYYHongMNZhangYet al. Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. (2018) 22:1034–46. doi: 10.1111/jcmm.13466

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 414

  GirardiGYarilinDThurmanJMHolersVMSalmonJE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. (2006) 203:2165–75. doi: 10.1084/jem.20061022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 415

  BanadakoppaMBalakrishnanMYallampalliC. Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells. Am J Reprod Immunol. (2018) 80:e13033. doi: 10.1111/aji.13033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 416

  MatsuyamaTTomimatsuTMimuraKYagiKKawanishiYKakiganoAet al. Complement activation by an angiogenic imbalance leads to systemic vascular endothelial dysfunction: A new proposal for the pathophysiology of preeclampsia. J Reprod Immunol. (2021) 145:103322. doi: 10.1016/j.jri.2021.103322

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 417

  SalehMCompagnoMPihlSStrevensHPerssonBWetteröJet al. Variation of complement protein levels in maternal plasma and umbilical cord blood during normal pregnancy: an observational study. J Clin Med. (2022) 11. doi: 10.3390/jcm11133611

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 418

  MiyanoANakayamaMFujitaTKitajimaHImaiSShimizuA. Complement activation in fetuses: assessment by the levels of complement components and split products in cord blood. Diagn Clin Immunol. (1987) 5:86–90.

  • Pubmed Abstract
  • Google Scholar

• 419

  HolersVMGirardiGMoLGuthridgeJMMolinaHPierangeliSSet al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. (2002) 195:211–20. doi: 10.1084/jem.200116116

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 420

  CohenDBuurmaAGoemaereNNGirardiGle CessieSScherjonSet al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol. (2011) 225:502–11. doi: 10.1002/path.2893

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 421

  ElfvingPKariniemiSKautiainenHRantalaihoVVirtaLJPuolakkaKet al. Pregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case-control study. Rheumatol Int. (2024) 44:1101–9. doi: 10.1007/s00296-024-05564-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 422

  TehCLWanSACheongYKLingGR. Systemic lupus erythematosus pregnancies: ten-year data from a single centre in Malaysia. Lupus. (2017) 26:218–23. doi: 10.1177/0961203316664996

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 423

  OngSGDingHJ. Predictors of adverse pregnancy outcome in a cohort of women with systemic lupus erythematosus in Malaysia. Med J Malaysia. (2021) 76:466–73.

  • Pubmed Abstract
  • Google Scholar

• 424

  LiuJZhaoYSongYZhangWBianXYangJet al. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. J Matern Fetal Neonatal Med. (2012) 25:261–6. doi: 10.3109/14767058.2011.572310

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 425

  Al-RiyamiNSalmanBAl-RashdiAAl-DughaishiTAl-HaddabiRHassanB. Pregnancy Outcomes in Systemic Lupus Erythematosus Women: A single tertiary centre experience. Sultan Qaboos Univ Med J. (2021) 21:e244–52. doi: 10.18295/squmj.2021.21.02.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 426

  EssoumaMNkeckJRMotolouzeKBignaJJTchaptchetPNkoroGAet al. Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review. Lupus Sci Med. (2020) 7. doi: 10.1136/lupus-2020-000400

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 427

  SalmonJEGirardiGHolersVM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus. (2003) 12:535–8. doi: 10.1191/0961203303lu397oa

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 428

  Castellanos GutierrezASFiguerasFMorales-PrietoDMSchleußnerEEspinosaGBañosN. Placental damage in pregnancies with systemic lupus erythematosus: A narrative review. Front Immunol. (2022) 13:941586. doi: 10.3389/fimmu.2022.941586

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 429

  OstensenMClowseM. Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol. (2013) 25:591–6. doi: 10.1097/BOR.0b013e328363ebf7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 430

  SteegersEAvon DadelszenPDuvekotJJPijnenborgR. Pre-eclampsia. Lancet. (2010) 376:631–44. doi: 10.1016/S0140-6736(10)60279-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 431

  SibaiBDekkerGKupfermincM. Pre-eclampsia. Lancet. (2005) 365:785–99. doi: 10.1016/S0140-6736(05)17987-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 432

  SibaiBM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. (2004) 103:981–91. doi: 10.1097/01.AOG.0000126245.35811.2a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 433

  DouglasKARedmanCW. Eclampsia in the United Kingdom. Bmj. (1994) 309:1395–400. doi: 10.1136/bmj.309.6966.1395

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 434

  VaughtAJGavriilakiEHueppchenNBlakemoreKYuanXSeifertSMet al. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp Hematol. (2016) 44:390–8. doi: 10.1016/j.exphem.2016.01.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 435

  VaughtAJBraunsteinEChaturvediSBlakemoreKBrodskyRA. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. J Matern Fetal Neonatal Med. (2022) 35:1392–400. doi: 10.1080/14767058.2020.1755650

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 436

  BurwickRMJavaAGrayKJCombsDRinconMRobertsVHet al. HELLP syndrome is characterized by a unique pattern of complement protein biomarkers. Am J Obstetrics Gynecology. (2022) 226:S484–5. doi: 10.1016/j.ajog.2021.11.802

  • CrossRef
  • Google Scholar

• 437

  ChenSZhengLYingdongHChenQ. Dysregulation of complement system in HELLP syndrome. Hypertension Pregnancy. (2021) 40:303–11. doi: 10.1080/10641955.2021.1983593

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 438

  ShahHBoyerTChenHChaturvediSVaughtABraunsteinEM. Complement activation drives progression of pre-eclampsia to HELLP syndrome. Blood. (2021) 138:772–2. doi: 10.1182/blood-2021-148162

  • CrossRef
  • Google Scholar

• 439

  VaughtAJBraunsteinEMJasemJYuanXMakhlinIEloundouSet al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. (2018) 3. doi: 10.1172/jci.insight.99128

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 440

  GerberGFBrodskyRAVaughtAJ. Complement C5 Inhibition in early onset HELLP Syndrome. Blood Adv. (2025) 9(13):3304–7. doi: 10.1182/bloodadvances.2024014746

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 441

  JivrajSAnstieBCheongY-CFairlieFMLairdSMLiTC. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. Hum Reprod. (2001) 16:102–6. doi: 10.1093/humrep/16.1.102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 442

  MaoDWuXDeppongCFriendLDDoleckiGNelsonDMet al. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity. (2003) 19:813–22. doi: 10.1016/S1074-7613(03)00321-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 443

  ZhouZXieHLiuMLiRJiangWZhengYet al. Expression and correlation of complement C3 and C4 in serum and maternal-fetal interface in patients with unexplained recurrent spontaneous abortion: A prospective cohort study. CEOG. (2023) 50. doi: 10.31083/j.ceog5011252

  • CrossRef
  • Google Scholar

• 444

  Sugiura-OgasawaraMNozawaKNakanishiTHattoriYOzakiY. Complement as a predictor of further miscarriage in couples with recurrent miscarriages. Hum Reprod. (2006) 21:2711–4. doi: 10.1093/humrep/del229

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 445

  KrogMCFlachsEMKolteAMde JagerWMeyaardLChristiansenOBet al. Angiogenic factors and the lectin pathway of complement in women with secondary recurrent pregnancy loss. J Reprod Immunol. (2024) 163:104221. doi: 10.1016/j.jri.2024.104221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 446

  MohlinFCMercierEFremeaux-BacchiVLiszewskiMKAtkinsonJPGrisJCet al. Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur J Immunol. (2013) 43:1617–29. doi: 10.1002/eji.201243196

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 447

  MohlinFCGrosPMercierEGrisJRBlomAM. Analysis of C3 gene variants in patients with idiopathic recurrent spontaneous pregnancy loss. Front Immunol. (2018) 9:1813. doi: 10.3389/fimmu.2018.01813

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 448

  LewisRDNarayanaswamyAKFarewellDReesDA. Complement activation in polycystic ovary syndrome occurs in the postprandial and fasted state and is influenced by obesity and insulin sensitivity. Clin Endocrinol (Oxf). (2021) 94:74–84. doi: 10.1111/cen.14322

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 449

  ButlerAEMoinASMSathyapalanTAtkinSL. Complement dysregulation in obese versus nonobese polycystic ovary syndrome patients. Cells. (2023) 12. doi: 10.3390/cells12152002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 450

  MoinASMSathyapalanTButlerAEAtkinSL. Classical and alternate complement factor overexpression in non-obese weight matched women with polycystic ovary syndrome does not correlate with vitamin D. Front Endocrinol (Lausanne). (2022) 13:935750. doi: 10.3389/fendo.2022.935750

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 451

  O’BrienTERayJGChanWS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology. (2003) 14:368–74. doi: 10.1097/01.EDE.0000059921.71494.D1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 452

  Canto-CetinaTCoral-VázquezRMRojano-MejíaDPérez GodoySCoronelACantoP. Higher prepregnancy body mass index is a risk factor for developing preeclampsia in Maya-Mestizo women: a cohort study. Ethn Health. (2018) 23:682–90. doi: 10.1080/13557858.2017.1315367

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 453

  VinturacheAMoledinaNMcDonaldSSlaterDToughS. Pre-pregnancy Body Mass Index (BMI) and delivery outcomes in a Canadian population. BMC Pregnancy Childbirth. (2014) 14:422. doi: 10.1186/s12884-014-0422-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 454

  SchiavoneMJPérezMPAquieriANosettoDPronottiMVMazzeiMet al. The role of obesity in the development of preeclampsia. Curr Hypertens Rep. (2024) 26:247–58. doi: 10.1007/s11906-024-01299-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 455

  ShimKBegumRYangCWangH. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes. (2020) 11:1–12. doi: 10.4239/wjd.v11.i1.1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 456

  MamaneYChung ChanCLavalleeGMorinNXuLJHuangJet al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes. (2009) 58:2006–17. doi: 10.2337/db09-0323

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 457

  PhielerJChungKJChatzigeorgiouAKlotzsche-von AmelnAGarcia-MartinRSprottDet al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol. (2013) 191:4367–74. doi: 10.4049/jimmunol.1300038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 458

  LynchAMEckelRHMurphyJRGibbsRSWestNAGiclasPCet al. Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol. (2012) 206:428.e421–428. doi: 10.1016/j.ajog.2012.02.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 459

  OlsonKNRedmanLMSonesJL. Obesity “complements” preeclampsia. Physiol Genomics. (2019) 51:73–6. doi: 10.1152/physiolgenomics.00102.2018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 460

  RobinsonDPKleinSL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. (2012) 62:263–71. doi: 10.1016/j.yhbeh.2012.02.023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 461

  Abu-RayaBMichalskiCSadaranganiMLavoiePM. Maternal immunological adaptation during normal pregnancy. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.575197

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 462

  ShererMLPosillicoCKSchwarzJM. An examination of changes in maternal neuroimmune function during pregnancy and the postpartum period. Brain Behavior Immun. (2017) 66:201–9. doi: 10.1016/j.bbi.2017.06.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 463

  BruntonPJ. Neuroactive steroids and stress axis regulation: Pregnancy and beyond. J Steroid Biochem Mol Biol. (2016) 160:160–8. doi: 10.1016/j.jsbmb.2015.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 464

  KopalianiIElsaidBSpeierSDeussenA. Immune and metabolic mechanisms of endothelial dysfunction. Int J Mol Sci. (2024) 25. doi: 10.3390/ijms252413337

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 465

  RizzoniDDe CiuceisCSzczepaniakPParadisPSchiffrinELGuzikTJ. Immune system and microvascular remodeling in humans. Hypertension. (2022) 79:691–705. doi: 10.1161/HYPERTENSIONAHA.121.17955

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 466

  ZengSHanMJiangMLiuFHuYLongYet al. Serum complement proteomics reveal biomarkers for hypertension disorder of pregnancy and the potential role of Clusterin. Reprod Biol Endocrinol. (2021) 19:56. doi: 10.1186/s12958-021-00742-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 467

  ZengSPanYLiuFYinJJiangMLongYet al. Role of clusterin in the regulation of trophoblast development and preeclampsia. Biochem Biophys Res Commun. (2021) 583:128–34. doi: 10.1016/j.bbrc.2021.10.064

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 468

  WatanabeHHamadaHYamadaNSohdaSYamakawa-KobayashiKYoshikawaHet al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. PROTEOMICS. (2004) 4:537–43. doi: 10.1002/pmic.200300565

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 469

  OztasEOzlerSErsoyAOIskenderCTSucakAErginMet al. Increased levels of serum clusterin is associated with intrauterine growth restriction and adverse pregnancy outcomes in preeclampsia. J Perinatal Med. (2016) 44:269–75. doi: 10.1515/jpm-2015-0120

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 470

  YaoSChenYCaoRLuLYangJLeiWet al. Clusterin from endometrial glands plays a critical role in decidualization via Trem2. BMC Genomics. (2024) 25:969. doi: 10.1186/s12864-024-10827-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 471

  DolgyrasPAnyfantiPLazaridisAGavriilakiEKoletsosNTriantafyllouAet al. Endothelial dysfunction and complement activation are independently associated with disease duration in patients with systemic vasculitis. Microvasc Res. (2024) 154:104692. doi: 10.1016/j.mvr.2024.104692

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 472

  KonukogluDUzunH. Endothelial dysfunction and hypertension. Adv Exp Med Biol. (2017) 956:511–40. doi: 10.1007/5584_2016_90

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 473

  WangZZhangZLiYZhangYWeiMLiHet al. Endothelial-derived complement factor D contributes to endothelial dysfunction in Malignant nephrosclerosis via local complement activation. Hypertension Res. (2023) 46:1759–70. doi: 10.1038/s41440-023-01300-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 474

  Cervia-HaslerCBrüningkSCHochTFanBMuzioGThompsonRCet al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. (2024) 383:eadg7942. doi: 10.1126/science.adg7942

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 475

  BaillieKDaviesHEKeatSBKLadellKMinersKLJonesSAet al. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med. (2024) 5:239–253.e235. doi: 10.1016/j.medj.2024.01.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 476

  WenzelUOKemperCBodeM. The role of complement in arterial hypertension and hypertensive end organ damage. Br J Pharmacol. (2021) 178:2849–62. doi: 10.1111/bph.15171

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 477

  KarthikeyanVJLipGY. Endothelial damage/dysfunction and hypertension in pregnancy. Front Biosci (Elite Ed). (2011) 3:1100–8. doi: 10.2741/314

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 478

  RamosAYoussefLMolinaPMartinez-SanchezJMoreno-CastañoABBlascoMet al. Endothelial damage and complement dysregulation in fetuses from pregnancies complicated by preeclampsia. Acta Obstetricia Gynecologica Scandinavica. (2025) 104(5):829–38. doi: 10.1111/aogs.15072

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 479

  ChenLFukudaNMatsumotoTAbeM. Role of complement 3 in the pathogenesis of hypertension. Hypertension Res. (2020) 43:255–62. doi: 10.1038/s41440-019-0371-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 480

  PenningMChuaJSvan KootenCZandbergenMBuurmaASchutteJet al. Classical complement pathway activation in the kidneys of women with preeclampsia. Hypertension. (2015) 66:117–25. doi: 10.1161/HYPERTENSIONAHA.115.05484

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 481

  DusseLMRiosDRAPinheiroMBCooperAJLwaleedBA. Pre-eclampsia: Relationship between coagulation, fibrinolysis and inflammation. Clinica Chimica Acta. (2011) 412:17–21. doi: 10.1016/j.cca.2010.09.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 482

  Drury-StewartDNHoppeKKLannertKWChungDWGammillHSJohnsenJM. Pregnancies complicated by severe preeclampsia exhibit perturbed von willebrand factor (VWF)-associated parameters. Blood. (2013) 122:3525. doi: 10.1182/blood.V122.21.3525.3525

  • CrossRef
  • Google Scholar

• 483

  Soleimani SamarkhazanHKhaksariMNRahmatiAEsfahaniMLSoloukiAAghaeiM. Von Willebrand disease (VWD) and pregnancy: a comprehensive overview. Thromb J. (2025) 23:41. doi: 10.1186/s12959-025-00727-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 484

  MCKAYDG. Hematologic evidence of disseminated intravascular coagulation in eclampsia. Obstetrical Gynecological Survey. (1972) 27:399–417. doi: 10.1097/00006254-197206000-00001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 485

  HeSBremmeKBlombäckM. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood coagulation fibrinolysis. (1997) 8:232–8. doi: 10.1097/00001721-199706000-00004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 486

  CarsonSDJohnsonDR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood. (1990) 76:361–7. doi: 10.1182/blood.V76.2.361.361

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 487

  HeurichMMcCluskeyG. Complement and coagulation crosstalk – Factor H in the spotlight. Immunobiology. (2023) 228:152707. doi: 10.1016/j.imbio.2023.152707

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 488

  MuhlfelderTWNiemetzJKreutzerDBeebeDWardPARosenfeldSI. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest. (1979) 63:147–50. doi: 10.1172/JCI109269

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 489

  IkedaKNagasawaKHoriuchiTTsuruTNishizakaHNihoY. C5a induces tissue factor activity on endothelial cells. Thromb Haemost. (1997) 77:394–8.

  • Pubmed Abstract
  • Google Scholar

• 490

  FoleyJHWaltonBLAlemanMMO’ByrneAMLeiVHarrasserMet al. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine. (2016) 5:175–82. doi: 10.1016/j.ebiom.2016.02.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 491

  AmaraUFlierlMARittirschDKlosAChenHAckerBet al. Molecular intercommunication between the complement and coagulation systems. J Immunol. (2010) 185:5628–36. doi: 10.4049/jimmunol.0903678

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 492

  AmaraURittirschDFlierlMBrucknerUKlosAGebhardFet al. Interaction between the coagulation and complement system. Adv Exp Med Biol. (2008) 632:71–9. doi: 10.1007/978-0-387-78952-1_6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 493

  YoussefLMirandaJBlascoMPaulesCCrovettoFPalomoMet al. Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Sci Rep. (2021) 11:3048. doi: 10.1038/s41598-021-82733-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 494

  QuintanillaBGreensteinDTripathiABartoshAYuanPZarateCAet al. Assessment of complement cascade components in patients with major depressive disorder. Brain Behavior Immun. (2025) 127:229–37. doi: 10.1016/j.bbi.2025.03.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 495

  RondungEMassoudiPNieminenKWickbergBPeiraNSilversteinRet al. Identification of depression and anxiety during pregnancy: A systematic review and meta-analysis of test accuracy. Acta Obstetricia Gynecologica Scandinavica. (2024) 103:423–36. doi: 10.1111/aogs.14734

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 496

  GaynesBNGavinNMeltzer-BrodySLohrKNSwinsonTGartlehnerGet al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005(119):1–8. doi: 10.1037/e439372005-001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar